KV1.3 potassium channel antagonist

Abstract

The present invention, K V 1.3 Potassium channel antagonists and their use in the treatment and management of inflammatory diseases, including neuroinflammatory diseases.

Description

[Technical Field]

[0001] The present invention, K V 1.3 Potassium channel antagonists and their use in the treatment and management of inflammatory diseases, including neuroinflammatory diseases. [Background technology]

[0002] K is a voltage-gated potassium channel. V 1,3 potassium channels are widely expressed in the immune and nervous systems and play important roles in the function of T cells and microglia.

[0003] T cell activation, proliferation, and effector function are related to K V 1.3 is strictly regulated by the interaction of ion channels, including channels. In T cells, K V 1.3 channels are involved in regulating calcium signaling, which is essential for T cell receptor (TCR) signaling and subsequent activation.

[0004] With TCR engagement, the membrane potential of T cells is depolarized, and voltage-dependent K V 1.3 channel opening occurs. As a result, potassium ions leach out, thereby stabilizing the membrane potential and promoting the opening of calcium channels. Calcium influx activates calcium-dependent signaling pathways that drive T cell activation, differentiation, and proliferation. Therefore, K V Inhibition of 1.3 channels can prevent T cell activation and proliferation, modulate the immune response, and potentially improve autoimmune and inflammatory conditions.

[0005] Microglia are commensal immune cells of the central nervous system (CNS) that are responsible for maintaining homeostasis and responding to injury or infection. In the context of neuroinflammation and neurodegenerative diseases, microglial activation contributes to the release of pro-inflammatory cytokines, chemokines, and reactive oxygen species (ROS), which can ultimately exacerbate neuronal damage.

[0006] K V 1.3 potassium channels have been found to play an essential role in the activation and function of microglia. In the resting state, microglia express low levels of K V 1.3 channels, but upon stimulation by inflammatory signals, the expression and activity of these channels increase significantly. This upregulation of K V 1.3 channels enhances the production of ROS and inflammatory cytokines, perpetuates the inflammatory response, and amplifies neuronal damage.

[0007] K V 1.3 channels' functional involvement in T cells and microglia suggests that their selective antagonism could be a promising therapeutic strategy for alleviating inflammation, particularly neuroinflammation associated with neurodegenerative diseases such as multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease. In preclinical studies, the use of K V 1.3 channel antagonists has been shown to suppress the activation and proliferation of T cells, reduce the activation of microglia, and decrease the production of inflammatory mediators. These effects manifest as reduced neuroinflammation and improved outcomes in animal models of neurodegenerative diseases such as Alzheimer's and Parkinson's diseases.

[0008] SUMMARY OF THE INVENTION

[0009] The present invention relates to a K V 1.3 potassium channel antagonist.

[0010] In one aspect, the present invention provides a compound of formula (I)

Chemical formula

[0011] In one aspect, the present invention is K V 1.3 The present invention relates to compounds of formula (I) as defined herein or pharmaceutically acceptable salts thereof, for use in the treatment of diseases or medical conditions in which inhibition of potassium channels is beneficial.

[0012] definition As used herein, the singular forms "a," "an," and "the" refer to multiple objects unless otherwise indicated by the context.

[0013] The terms “approximately” and “about” as used herein are synonymous. In some embodiments, “about” refers to a stated quantity, value, or period of ±20%, ±10%, ±5%, ±4%, ±3%, ±2%, ±1%, or ±0.5%.

[0014] As used herein, the term “antagonist” refers to any compound that inhibits (e.g., antagonizes, reduces, diminishes, blocks, reverses, or modifies) the effect of a given agonist on a protein (including the protein itself). More specifically, an antagonist can act relative to the activity of a protein, resulting in a reduction of the biological activity of the natural agonist in a way that antagonizes (e.g., counteracts, reverses, or is contrary to) the protein’s original action. The terms “antagonist,” “inhibitor,” and “blocker” are used interchangeably herein. V This refers to drugs that reduce or suppress biological activity, such as those that inhibit the activity of ion channels like 1.3.

[0015] As used herein, the term “compound” is intended to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structure shown, unless otherwise specified.

[0016] "C 1~3 "Alkyl" and "C 1~6 The term "alkyl," as used herein, refers to a straight or branched hydrocarbon chain containing 1 to 3 and 1 to 6 carbon atoms, respectively. 1~3 Alkyl and C 1~6 Typical examples of alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, sec-butyl, isobutyl, tert-butyl, pentyl, and hexyl.

[0017] "C 3~6 As used herein, the term "cycloalkyl" refers to a saturated carbocyclic molecule whose cyclic skeleton has 3 to 6 carbon atoms. 3~6Typical examples of cycloalkyl compounds include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, and cyclohexyl.

[0018] "C 1~3 The term "alkoxy" is used herein as -OR # This refers to R # C as defined herein 1~3 Represents alkyl. C 1~3 Typical examples of alkoxys include methoxy, ethoxy, propoxy, and isopropoxy.

[0019] As used herein, the term "halogen" refers to -F, -Cl, -Br, or -I. In some embodiments, the halogen is F. In some embodiments, the halogen is Cl.

[0020] As used herein, the term "pharmaceutically acceptable salt" refers to a salt that, within the bounds of appropriate medical judgment, is suitable for use in contact with human and lower animal tissues without causing excessive toxicity, irritation, or allergic reactions, and that provides a reasonable benefit-risk ratio. Pharmacologically acceptable salts are well known in the art.

[0021] As used herein, the term “spiro compound” refers to a compound having one atom (usually a quaternary carbon) as the sole common member atom of two rings. 5~8 As used herein, the term “spiroalkyl” refers to a bicyclic ring system containing 5 to 8 carbon atoms, in which two rings are connected by a single common carbon atom. 5~8 Typical examples of spiroalkyls include, but are not limited to, spiro[2.2]pentanyl, spiro[3.2]hexanyl, spiro[3.3]heptanyl, spiro[3.4]octanyl, and spiro[2.5]octanyl.

[0022] As described herein, the compounds of the present invention may contain “substituted” moieties. Generally, the term “substituted” means that one or more hydrogens of a given moiety are replaced with preferred substituents. Unless otherwise indicated, an “optionally substituted” group may have preferred substituents at one or more substituted positions of the group, and if two or more positions in any given structure are replaced with two or more substituents selected from a particular group, the substituents may be the same or different at all positions, i.e., the substituents can be selected individually / independently from the group of substituents. The substituent combinations envisioned by the present invention are preferably combinations that result in the formation of stable or chemically feasible compounds.

[0023] In some embodiments, the chemical group is a "bond," which may be described as the absence of the chemical group. For example, CH3-R a -R in OH a If it is a "bond," then this refers to CH3OH.

[0024] In some embodiments, the two R groups are linked together to form a ring, i.e., the ring is formed by the two R groups and intervening atoms(s).

[0025] As used herein, the term “stable” means a compound that remains substantially unchanged when produced, detected, and, in certain embodiments, recovered, purified, and used for one or more of the purposes disclosed herein. [Modes for carrying out the invention]

[0026] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and X 4 is C(R 17 )(R 18 ), O or C(O), X 5 is C(R 19 )(R 20 ) or combination, X 6 is a bond or C(R 21 )(R 22 ) and Here, R 9 and R 11 , R 9 and R 13 , R 10 and R 11 , R 10 and R 13 , R 13 and R 17 , R 13 and R 18 , or R 14 and R 15 They may bond together and form a ring with intervening atoms(s), R7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 9 R 11 Or R 13 When connected to form a ring, R 9 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 10 R 11 Or R 13 When connected to form a ring, R 10 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is -X 13-R 33 And, X 13 is a combination, C 1~3 C may be substituted with alkyl. 1~3 Alkanedyl, -O-, or C 1~3 It is an alkanedyl-O-, R 33 C 1~3 Alkyl, C 3~6 Cycloalkyl, C 1~3 A C selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and morpholinyl, each of which may be substituted with a halogen, one or more fluorine atoms. 1~3 C may be substituted with alkoxy or one or more F atoms. 1~3 It may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. or R 11 R 9 Or R 10 When connected to form a ring, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 13 R 9 , R 10 , R 17 , or R 18 When connected to form a ring, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 17 R 13 When connected to form a ring, R 17 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 18 R 13 When connected to form a ring, R 18 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) and However, X 2 If X is a join, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) (is) This relates to the compound or its pharmaceutically acceptable salt.

[0027] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and X 4 is C(R 17 )(R 18 ), O or C(O), X 5 is C(R 19 )(R 20 ) or combination, X 6 is a bond or C(R 21 )(R 22 ) and Here, R 9 and R 11 , R 9 and R 13 , R 10 and R 11 , R 10 and R 13 , R 13 and R 17 , R 13 and R 18 , or R 14 and R 15 They may bond together and form a ring with intervening atoms(s), R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 9 R 11 Or R 13 When connected to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 10 R 11 Or R 13 When connected to form a ring, R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, and morpholinyl, where, • C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 The azetidinyl may be substituted with one or more substituents individually selected from the group consisting of alkoxy, morpholinyl, azetidinyl, -O-azetidinyl, and -O-oxetanyl, wherein the azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. • C 3~5 Cycloalkyls are halogens, and C1~3 It may be substituted with one or more substituents selected from alkoxys. The pyridinyl molecule may be substituted with one or more NH2 groups. • The pyrrolidinil in question is C 1~3 Alkyl, halogen, C 1~3 Alkoxy, C 1~3 The molecules may be substituted with one or more substituents individually selected from the group consisting of haloalkyl, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • This azetidinyl contains halogens, C 1~3 It may be substituted with one or more substituents selected from alkyl and NH2. • The morpholinyl in question is C 1~3 Is it acceptable for it to be substituted with alkyl? or R 11 R 9 Or R 10 When connected to form a ring, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 13 R 9 , R 10 , R 17 , or R 18 When connected to form a ring, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 17 R 13 When connected to form a ring, R 17 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 18 R 13 When connected to form a ring, R 18 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 This relates to compounds of ) ) ) or pharmaceutically acceptable salts thereof.

[0028] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl or halogen such as F, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, • C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The pyrrolidinil in question is C 1~3 Alkyl, halogen, C 1~3The molecule may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The azetidinyl may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 5 is C(R 19 )(R 20 ) or combination, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 6 is a bond or C(R 21 )(R 22 ) and R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) This relates to the compound or its pharmaceutically acceptable salt.

[0029] In some embodiments, X 3 is N(C(O)R 11 ) or N(R 16 ) if X 2 This is not a bond. In some embodiments, X 3 is N(C(O)R 11 ) or N(R 16 ) if X 5 and X 6 They cannot both be in a combination.

[0030] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, • C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The pyrrolidinil in question is C 1~3 Alkyl, halogen, C 1~3 The molecule may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The azetidinyl may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 5 is C(R 19 )(R 20 ) or combination, R 19is C optionally substituted with H and 1 to 3 Fs 1~3 is alkyl or a halogen such as F, R 20 is C optionally substituted with H and 1 to 3 Fs 1~3 is alkyl or a halogen such as F, X 6 is a bond or C(R 21 )(R 22 ), R 21 is C optionally substituted with H and 1 to 3 Fs 1~3 is alkyl or a halogen such as F, R 22 is C optionally substituted with H and 1 to 3 Fs 1~3 is alkyl or a halogen such as F, R 7 R, 8 R, 9 R, 10 R, 17 R, 18 R, 19 R, 20 R, 21 R, and 22 any two of them may be linked together to form a ring, provided that when X 4 is O, X 3 is C(R 12 )(C(O)R 13 ), and R 13 is NH2, N(H)(CH3) or N(CH3)2, provided that when X 3 is N(R 16 ), X 4 is C(O), provided that when X 4 is C(O), X 3 is N(R 16 ), provided that when X 3 is N(C(O)R 11 ) or N(R 16 ), X 2 is not a bond, provided that when X 3 is N(C(O)R 11) or N(R 16 ) and when X 5 and X 6 are not both bonds) is) relates to a compound of or a pharmaceutically acceptable salt thereof.

[0031] In one aspect, the present invention provides a compound of formula (I) [Chemical formula] (wherein R 1 is halogen or H, R 2 is halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is of formula (II): [Chemical formula] (wherein X 1 is C(R 7 )(R 8 ), R 7 is H, C 1~3 alkyl optionally substituted with 1 to 3 Fs, or F, R 8 is H, C 1~3 alkyl optionally substituted with 1 to 3 Fs, or F, X 2 is C(R 9 )(R 10 ) or a bond, AR<000​​​​​​​​​​​3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, a. C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys. b. The pyridinyl may be substituted with one or more NH2 groups. c. The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. d. The azetidinil may be substituted with NH2. eR 11 C 1~3 Alkyl or C 1~3 If it is an alkoxy, R 11 is R 9 or R 10 They may be connected to form a ring, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, a. The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. b. The azetidinyl may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and X 7 is a bond or CH2, R 23 is H or C 1~3 alkyl, or R 23 is a bond, R 15 is C 1~3 alkanediyl, and R 23 is R 15 and is linked to form a 4- or 5-membered ring, R 24 is C 1~3 alkyl, R 15 is H or C 1~3 alkyl, R 16 is H or C 1~3 alkyl, X 4 is C(R 17 )(R 18 )), O, or C(O), R 17 is H, C 1~3 alkyl optionally substituted with 1 to 3 Fs, or F, R 18 is H, C 1~3 alkyl optionally substituted with 1 to 3 Fs, or F, X 5 is C(R 19 )(R 20 ) or a bond, R 19 is H, C 1~3 alkyl optionally substituted with 1 to 3 Fs, or F, R 20C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, X 6 is a bond or C(R 21 )(R 22 ) and R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )(C(O)R 13 ) and R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) This relates to the compound or its pharmaceutically acceptable salt.

[0032] Therefore, in this embodiment, the present invention is defined by formula (XIII): [ka] (In the formula, R 1 , R 2 , R 3 , R 5 , R6 , X 1 , X 2 , X 3 , X 4 , X 5 , and X 6 This relates to compounds of (as defined herein) or pharmaceutically acceptable salts thereof.

[0033] In one embodiment, the present invention relates to formula (I) (wherein R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 This relates to compounds of (as defined herein) or pharmaceutically acceptable salts thereof.

[0034] In one embodiment, the present invention relates to formula (LVII) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 9 and R 11 or R 10 and R 11 They may bond together and form a ring with the intervening atom. R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3Alkyl, or halogen such as F, or R 9 R 11 When connected to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 10 R 11 When connected to form a ring, R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, and morpholinyl, where, • C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 The azetidinyl may be substituted with one or more substituents individually selected from the group consisting of alkoxy, morpholinyl, azetidinyl, -O-azetidinyl, and -O-oxetanyl, wherein the azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. • C 3~5 Cycloalkyls are halogens, and C 1~3 It may be substituted with one or more substituents selected from alkoxys. The pyridinyl molecule may be substituted with one or more NH2 groups. • The pyrrolidinil in question is C 1~3 Alkyl, halogen, C 1~3 Alkoxy, C1~3 The molecules may be substituted with one or more substituents individually selected from the group consisting of haloalkyl, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • This azetidinyl contains halogens, C 1~3 It may be substituted with one or more substituents selected from alkyl and NH2. • The morpholinyl in question is C 1~3 Is it acceptable for it to be substituted with alkyl? or R 11 R 9 Or R 10 When connected to form a ring, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R18 , R 19 , and R 20 The invention relates to a compound of (any two of which may be linked together to form a ring) or a pharmaceutically acceptable salt thereof.

[0035] In one embodiment, the present invention relates to formula (LVII) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 It is a halogen, R 5 , R 6 , R 8 , R 17 , R 18 , R 19 , and R 20 H is H, R 9 and R 11 or R 10 and R 11 R 33 They may bond together via an intermediary atom, forming a ring with the intervening atom. R 7 C may be replaced by H, or 1 to 3 F. 1~3 It is alkyl, R 10 Is H or R 10 R 11 When connected to form a ring, R 10 is a combination or C 1~3 It is Alkandil, R 9 Is H or R 9 R 11 When connected to form a ring, R 9 is a combination or C 1~3 It is Alkandil, R 11 is -X 13 -R 33 And, X 13is a combination, C 1~3 C may be substituted with alkyl. 1~3 Alkanediyl, -O-, or C 1~3 It is an alkanedyl-O-, R 33 C 1~3 Alkyl, azetidinyl, pyrrolidinyl, oxetanyl, and tetrahydrofuranyl, each of which may be substituted with one or more F, or R 11 R 33 via R 9 Or R 10 When connected to form a ring, R 33 is a combination or C 1~3 (It is Arcandil) This relates to the compound or its pharmaceutically acceptable salt.

[0036] In some embodiments, the compound of formula (LVII) is formula LVIIa): [ka] That is the case.

[0037] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is formula (XXIV), formula (XXV), formula (XXVI), or formula (XXVII): [ka] (In the formula, R 7is C optionally substituted with H and 1 to 3 F 1~3 is alkyl or a halogen such as F, R 8 is C optionally substituted with H and 1 to 3 F 1~3 is alkyl or a halogen such as F, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ), R 9 is C optionally substituted with 1 to 3 halogens 1~3 is alkyl or a halogen such as F, R 10 is C optionally substituted with 1 to 3 halogens 1~3 is alkyl or a halogen such as F, R 11 is selected from the group consisting of C 1~3 alkyl, C 3~5 cycloalkyl, C 1~3 alkoxy, pyridinyl, azetidinyl and pyrrolidinyl, where · said C 1~3 alkyl may be optionally substituted with one or more substituents individually selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, C 1~3 alkoxy, and morpholinyl, · said pyridinyl may be optionally substituted with one or more NH2, · said pyrrolidinyl may be optionally substituted with one or more substituents individually selected from the group consisting of C 1~3 alkyl, halogen, C 1~3 alkoxy, NH2, N(H)(CH3), N(CH3)2 and azetidinyl, and said azetidinyl may be optionally substituted with one or more halogens,<00079​​​​​9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The azetidinyl may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. (is) This relates to the compound or its pharmaceutically acceptable salt.

[0038] In some embodiments, R 4 The equation is (XXV), and X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) In some embodiments, R 4 is equation (XXVI), and X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) In some embodiments, R 4 is equation (XXVII), and X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) In some embodiments, R 4 Equation (XXIV) is given by X 4 is C(R 17 )(R 18 ) or C(O).

[0039] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 This refers to formulas (III), (XXXIV), (XXXV), (XXXVI), (XXXVII), (XXXVIII), (XXXIX), or (XL): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, • C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The pyrrolidinil in question is C 1~3 Alkyl, halogen, C 1~3 The molecule may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The azetidinyl may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. (is) This relates to the compound or its pharmaceutically acceptable salt.

[0040] In some embodiments, the compound is K V 1.3 It is a potassium channel inhibitor.

[0041] In some embodiments, R 1 is a halogen. In some embodiments, R 1 is Cl. In some embodiments, R 1 is F. In some embodiments, R 1 is H. In some embodiments, R 2 is Cl. In some embodiments, R 3 is a halogen. In some embodiments, R 3 is Cl. In some embodiments, R 3 is F. In some embodiments, R 3 is H. In some embodiments, R 5 is H. In some embodiments, R 5 is a halogen. In some embodiments, R 5 is F. In some embodiments, R 6 is H. In some embodiments, R 6 is a halogen. In some embodiments, R 6 is F. In some embodiments, R 1 is F or Cl, and R 2 is Cl, and R 3 is Cl, and R 5 H is R 6 is H. In some embodiments, R 5 H is R 6 is H. In some embodiments, R 1 is a halogen, and R 2 is a halogen. In some embodiments, R 2 is a halogen, and R 3 is a halogen. In some embodiments, R 1 is a halogen, and R 2 is a halogen, and R 3 is a halogen. In some embodiments, R 1 is a halogen, and R 2 is a halogen, and R 3 is a halogen, and R 5 H is R 6 is H. In some embodiments, R 1 is a halogen, and R 2is a halogen, and R 3 H is R 5 H is R 6 is H. In some embodiments, R 1 is a halogen, and R 2 is a halogen, and R 3 H is R 5 is a halogen, and R 6 is H. In some embodiments, R 1 is a halogen, and R 2 is a halogen, and R 3 H is R 5 H is R 6 is a halogen. In some embodiments, R 1 H is R 2 is a halogen, and R 3 is a halogen, and R 5 H is R 6 is H. In some embodiments, R 1 is F or Cl, and R 2 is Cl or F, and R 3 is Cl or F. In some embodiments, R 1 F is R 2 is Cl, and R 3 is Cl. In some embodiments, R 1 F is R 2 is Cl, and R 3 is F. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 is Cl. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 is F. In some embodiments, R 1 is F or Cl, and R 2 is Cl or F, and R 3 is Cl or F, and R 5 H is R 6 is H. In some embodiments, R 1 F is R 2 is Cl, and R 3 is Cl, and R5 H is R 6 is H. In some embodiments, R 1 F is R 2 is Cl, and R 3 F is R 5 H is R 6 is H. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 is Cl, and R 5 H is R 6 is H. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 F is R 5 H is R 6 is H. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 H is R 5 F is R 6 is H. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 H is R 5 H is R 6 is F. In some embodiments, R 1 is Cl, and R 2 is Cl, and R 3 H is R 5 H is R 6 is H. In some embodiments, R 1 F is R 2 is Cl, and R 3 H is R 5 H is R 6 is H. In some embodiments, R 1 H is R 2 is Cl, and R 3 is Cl, and R 5 H is R 6 H is H.

[0042] In some embodiments, X 6is a bond. In some embodiments, X 7 is a bond. In some embodiments, X 7 is C 1~3 It is an alkanedyl. In some embodiments, X 7 It is CH2.

[0043] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 Equation (XXIV): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 19 , R 20 , X 3 , and X 4 R is as defined herein. In some embodiments, R 4 is equation (XXIV) (where R 7 , R 8 , R 9 , R 10 , R 19 , R 20 , and X 3 X is defined as described herein, 4 is C(R 17 )(R 18 ) or C(O)). In some embodiments, X 2 is C(R 9 )(R 10 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 is equation (XXVIII): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , and X 3 (as defined herein).

[0044] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 Equation (III): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 11 , R 17 , R 18 , R 19 , and R 20 (as defined herein).

[0045] In some embodiments, R 4 Equation (IV): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 11 , R 17 , R 18 , R19 , and R 20 (as defined herein).

[0046] In some embodiments, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 4 Equation (V): [ka] (In the formula, R 11 (is defined herein).

[0047] In some embodiments, R 7 CH3 and other C 1~3 It is alkyl, R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 8 CH3 and other C 1~3 It is alkyl, R 7 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 7 and R 8 CH3 and other C 1~3 It is alkyl, R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 17 CH3 and other C 1~3 It is alkyl, R 7 , R 8 , R 9 , R10 , R 18 , R 19 , and R 20 is H. In some embodiments, R 18 CH3 and other C 1~3 It is alkyl, R 7 , R 8 , R 9 , R 10 , R 17 , R 19 , and R 20 is H. In some embodiments, R 17 and R 18 CH3 and other C 1~3 It is alkyl, R 7 , R 8 , R 9 , R 10 , R 19 , and R 20 is H. In some embodiments, R 8 and R 17 CH3 and other C 1~3 It is alkyl, R 7 , R 9 , R 10 , R 18 , R 19 , and R 20 is H. In some embodiments, R 11 R 9 or R 10 When R is connected to form a ring, 9 or R 10 is R 11 R 33 It connects to R, that is, 9 or R 10 and R 11 That is, R 33 They bond together via R, forming a ring with the intervening atoms. In some embodiments, R 9 is R 33 It connects to form a ring. In some embodiments, R 10 is R 33 It connects to form a ring. In some embodiments, R 11 is C 1~3 Alkyl or C 1~3 It is an alkoxy, R 9 H is R 10It is a bond, R 11 is R 10 It connects to form a ring. In some embodiments, R 11 is C 1~3 Alkyl or C 1~3 It is an alkoxy, R 10 H is R 9 It is a bond, R 11 is R 9 It connects to form a ring.

[0048] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(R 16 ) and X 4 is C(O) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 is equation (XXXIV): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 16 , R 19 , and R 20 R is as defined herein. In some embodiments, R 4 is formula (XLI): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 16 , R 19 , and R 20 (as defined herein).

[0049] In some embodiments, R 4 Equation (VI): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 It is alkyl.

[0050] In some embodiments, R 4 Equation (VIA-1): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 It is alkyl. In some embodiments, R 4 Equation (VIA-2): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 It is alkyl.

[0051] In some embodiments, R 4 Equation (VIB-1): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 It is alkyl. In some embodiments, R 4 Equation (VIB-2): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 It is alkyl.

[0052] In some embodiments, R 7 and R 19 These are linked together to form a bridging biringle. In some embodiments, R 8 and R 20 These are linked together to form a bridging biringle. In some embodiments, R 9 and R 17 These are linked together to form a bridging biringle. In some embodiments, R 10 and R 18 These are linked together to form a bridging biringle. In some embodiments, R 9 and R 19 These are linked together to form a bridging biringle. In some embodiments, R 10 and R 20 These are linked together to form a bridging biringle. In some embodiments, R 7 and R 17 These are linked together to form a bridging biringle. In some embodiments, R 8 and R 18 They connect together to form a bridged biring ring.

[0053] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 7 and R 19 These are linked together to form a bridging biringle ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19)(R 20 ) and X 6 It is a bond, R 8 and R 20 They link together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof.

[0054] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 9 and R 17 These are linked together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 10 and R 18 They link together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof.

[0055] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R9 and R 19 These are linked together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 10 and R 20 They link together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof.

[0056] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 7 and R 17 These are linked together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 8 and R 18 They link together to form a bridging bicyclic ring or a pharmaceutically acceptable salt thereof.

[0057] In some embodiments, R 4 is equation (VII), equation (VIII), or equation (IX): [ka] (In the formula, R 11 (where w is as defined herein, and w is 1 or 2).

[0058] In some embodiments, R 4 is equation (VII). In some embodiments, R 4 is equation (VII), where w is 1. In some embodiments, R 4 is equation (VII), where w is 2. In some embodiments, equation (VIII). In some embodiments, R 4 is equation (VIII), where w is 1. In some embodiments, R 4 is equation (VIII), where w is 2. In some embodiments, R 4 is given by equation (IX). In some embodiments, R 4 Equation (IX) is given by , where w is 2.

[0059] In some embodiments, X 2 is a combination, X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 )

[0060] In some embodiments, R 4 is equation (XXVII): [ka] (In the formula, R 7 , R 8 , R 19 , R 20 , R 21 , R 22 , X 3 and X 4 R is as defined herein. In some embodiments, R4 is equation (XXVII) (where R 7 , R 8 , R 19 , R 20 , R 21 , R 22 , X 4 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ), or C(R 14 )(R 15 ) is ) is. In some embodiments, R 4 is equation (XXXI): [ka] (In the formula, R 7 , R 8 , R 19 , R 20 , R 21 , R 22 , X 3 and X 4 R is as defined herein. In some embodiments, R 4 is equation (XXXI) (where R 7 , R 8 , R 19 , R 20 , R 21 , R 22 , X 4 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ), or C(R 14 )(R 15 ) is ) is.

[0061] In some embodiments, X 2 is a combination, X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 ) In some embodiments, R 4is equation (XXXII): [ka] (In the formula, R 7 , R 8 , R 17 , R 18 , R 19 , R 20 , R 21 , R 22 , and X 3 (as defined herein).

[0062] In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 ) In some embodiments, R 4 is formula (XXXIX): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 R is as defined herein. In some embodiments, R 4 is equation (XLVII): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18R is as defined herein. In some embodiments, R 4 is formula (XLVIII): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 (as defined herein).

[0063] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 is equation (XXXV): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 14 , R 15 , R 17 , R 18 , R 19 , and R 20 R is as defined herein. In some embodiments, R 4 Equation (XLII): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R14 , R 15 , R 17 , R 18 , R 19 , and R 20 (as defined herein).

[0064] In some embodiments, X 2 is a combination, X 4 is O, X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 ) In some embodiments, R 4 is equation (XXXIII): [ka] (In the formula, R 7 , R 8 , R 19 , R 20 , R 21 , R 22 , and X 3 R is as defined herein. In some embodiments, R 4 is equation (XXXIII) (where R 7 , R 8 , R 19 , R 20 , R 21 , R 22 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) is ) is.

[0065] In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is O, X 5 is C(R 19 )(R 20 ) and X 6 is C(R21 )(R 22 ) In some embodiments, R 4 is formula (XL): [ka] (In the formula, R 7 , R 8 , R 12 , R 13 , R 19 , R 20 , R 21 , and R 22 R is as defined herein. In some embodiments, R 4 is formula (XLIX): [ka] (In the formula, R 7 , R 8 , R 12 , R 13 , R 19 , R 20 , R 21 , and R 22 R is as defined herein. In some embodiments, R 4 Equation (L): [ka] (In the formula, R 7 , R 8 , R 12 , R 13 , R 19 , R 20 , R 21 , and R 22 (as defined herein).

[0066] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6 It is a combination.

[0067] In some embodiments, R 4 is equation (XXVI): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , and X 3 R is as defined herein. In some embodiments, R 4 is equation (XXVI) (where R 7 , R 8 , R 9 , R 10 , R 17 , R 18 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) is ) is. In some embodiments, R 4 is formula (XXX): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , and X 3 R is as defined herein. In some embodiments, R 4 is formula (XXX) (where R 7 , R 8 , R 9 , R 10 , R 17 , R 18 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) is ) is.

[0068] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6 is a bond. In some embodiments, R 4 is equation (XXXVIII): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 R is as defined herein. In some embodiments, R 4 The formula is (XLV): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 R is as defined herein. In some embodiments, R 4 is equation (XLVI): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 R is as defined herein. In some embodiments, R 4 is equation (Xa) or equation (Xb): [ka] (In the formula, R 12 and R 13 (as defined herein).

[0069] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and R 13 R 9 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 9 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 6 It is a bond, R 13 R 9 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6It is a bond, R 13 R 9 It connects with the intervening atom to form a ring. In some embodiments, R 4 Equation (LIII): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 is bonded, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0070] In some embodiments, R 4 is equation (LIIIa): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 (as defined herein). In some embodiments, the part of formula (LIII) is formula (LIIIa).

[0071] In some embodiments, R 4 is equation (LIII) or equation (LIIIa), and R 7 , R 8 , R 10 , R 12 , R 17 , and R 18 is H. In some embodiments, R 4 is equation (LIII) or equation (LIIIa), and R 13 is -N(CH3)-. In some embodiments, R 4 is equation (LIII) or equation (LIIIa), and R 9 It is -CH2-.

[0072] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and R 13 R 10 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 10 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 6 It is a bond, R 13 R 10 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6 It is a bond, R 13 R 10 It connects with the intervening atom to form a ring. In some embodiments, R 4 The formula is (LIV): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 10 is bonded, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 12 C may be substituted with H and 1 to 3 F. 1~3Alkyl or halogen such as F, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0073] In some embodiments, R 4 is equation (LIVa): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 12 , R 13 , R 17 , and R 18 (As defined herein). In some embodiments, the part of formula (LIV) is formula (LIVa).

[0074] In some embodiments, R 4 is equation (LIV) or equation (LIVa), and R 7 , R 8 , R 9 , R 12 , R 17 , and R 18 is H. In some embodiments, R 4 is equation (LIV) or equation (LIVa), and R 13 is -N(CH3)-. In some embodiments, R 4 is equation (LIV) or equation (LIVa), and R 10 It is -CH2-.

[0075] In some embodiments, X 2is a combination, X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a combination.

[0076] In some embodiments, R 4 is equation (XXV): [ka] (In the formula, R 7 , R 8 , R 17 , R 18 , R 19 , R 20 , and X 3 R is as defined herein. In some embodiments, R 4 is equation (XXV) (where R 7 , R 8 , R 17 , R 18 , R 19 , R 20 X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) is ) is. In some embodiments, R 4 Equation (XXIX): [ka] (In the formula, R 7 , R 8 , R 17 , R 18 , R 19 , R 20 , and X 3 R is as defined herein. In some embodiments, R 4 is equation (XXIX) (where R 7 , R 8 , R 17 , R 18 , R 19 , R 20X is defined as described herein, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) is ) is.

[0077] In some embodiments, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 17 It connects with the intervening atom to form a ring. In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 17 It connects with the intervening atom to form a ring. In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 ) and R 13 R 17 It connects with the intervening atom to form a ring. In some embodiments, R 4 is equation (LV): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 17 is bonded, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0078] In some embodiments, R 4 is equation (LVa): [ka] (In the formula, R 7 , R 8 , R 12 , R 13 , R17 , R 18 , R 19 , R 20 , R 21 and R 22 (is as defined herein). In some embodiments, the part of formula (LV) is formula (LVa).

[0079] In some embodiments, R 4 is equation (LV) or equation (LVa), and R 7 , R 8 , R 12 , R 18 , R 19 , R 20 , R 21 , and R 22 is H. In some embodiments, R 4 is equation (LV) or equation (LVa), and R 13 is -N(CH3)-. In some embodiments, R 4 is equation (LV) or equation (LVa), and R 17 It is -CH2-.

[0080] In some embodiments, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 18 It connects with the intervening atom to form a ring. In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17 )(R 18 ) and R 13 R 18 It connects with the intervening atom to form a ring. In some embodiments, X 2 is a combination, X 3 is C(R 12 )(C(O)R 13 ) and X 4 is C(R 17)(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is C(R 21 )(R 22 ) and R 13 R 18 It connects with the intervening atom to form a ring. In some embodiments, R 4 Equation (LVI): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 17 is bonded, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0081] In some embodiments, R 4 is equation (LVIa): [ka] (In the formula, R 7 , R 8 , R 12 , R 13 , R 17 , R 18 , R 19 , R 20 , R 21 and R 22 (is as defined herein). In some embodiments, the part of formula (LV) is formula (LVb).

[0082] In some embodiments, R 4 is equation (LVI) or equation (LVIa), and R 7 , R 8 , R 12 , R 18 , R 19 , R 20 , R 21 , and R 22 is H. In some embodiments, R 4 is equation (LVI) or equation (LVIa), and R 13 is -N(CH3)-. In some embodiments, R 4 is equation (LVI) or equation (LVIa), and R 17 It is -CH2-.

[0083] In some embodiments, X 2 is a combination, X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17)(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 4 is equation (XXXVI): [ka] (In the formula, R 7 , R 8 , R 14 , R 15 , R 17 , R 18 , R 19 , and R 20 R is as defined herein. In some embodiments, R 4 is equation (XLIII): [ka] (In the formula, R 7 , R 8 , R 14 , R 15 , R 17 , R 18 , R 19 , and R 20 (as defined herein).

[0084] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6 is a bond. In some embodiments, R 4 Equation (XI): [ka] (In the formula, R 14 is -X 7 N(R 23)(C(O)R 24 ) and X 7 is a bond or CH2, R 23 is H or C 1~3 Alkyl or R 23 It is a bond, R 15 is C 1~3 It is an alkanedyl, R 23 is R 15 It connects to form a 4 or 5-membered ring, R 24 is C 1~3 It is alkyl, R 15 is H or C 1~3 (It is alkyl.) That is the case.

[0085] In some embodiments, X 2 is a combination, X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17 )(R 18 ) and X 5 is a combination, X 6 is a bond. In some embodiments, R 4 is equation (XXXVII): [ka] (In the formula, R 7 , R 8 , R 14 , R 15 , R 17 , and R 18 R is as defined herein. In some embodiments, R 4 is equation (XLIV): [ka] (In the formula, R 7 , R 8 , R 14 , R 15 , R 17 , and R 18(as defined herein).

[0086] In some embodiments, R 14 and R 15 These are linked together to form a 5-membered ring. In some embodiments, R 14 and R 15 They connect together to form a four-membered ring.

[0087] In some embodiments, R 14 and R 15 They connect together to form a ring, R 14 is -X 9 C(O)X 11 -and here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 15 is a combination or C 1~3 It is Arcanziel.

[0088] In some embodiments, R 4 Equation (XVI): [ka] (In the formula, R 14 and R 15 They connect together to form a ring, R 14 is -X 9 C(O)X 11 -and, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 15 is a combination or C 1~3 (It is Arcandil) That is the case.

[0089] In some embodiments, R 4 is equation (XIX): [ka] (In the formula, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 10 is -C(O)-, -CH2-, or a bond, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, X 12 is -N(C(O)R 24 )- or combination, m is either 1 or 2. n is either 0 or 1. z is either 1 or 2, However, X 10 If X is -C(O)-, 12 It is a combination, However, X 10 If it is a -CH2- or bond, X 12 is -N(C(O)R 24 )-, where ring A is a 4- to 6-membered ring. That is the case.

[0090] In one embodiment, the present invention relates to formula (XXII): [ka] (In the formula, R 1 , R 2 , R 3 , R 5 , R 6 , X 9 , X 10 , X 11 , X 12 The present invention relates to compounds of (where m, n, and z are as defined herein).

[0091] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 14 and R 15 They connect together to form a ring.

[0092] In some embodiments, X 7 It is a bond, R 23 is H or C 1~3 It is alkyl, R 24 is C 1~3 It is alkyl, R 15 is H or C 1~3 It is alkyl. In some embodiments, X 2 is a combination, X 3 is C(R 14 )(R 15 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 is a bond. In some embodiments, R 14 and R 15They are linked together to form a ring. In some embodiments, R 23 It is a bond, R 15 is C 1~3 It is an alkanedyl, R 23 is R 15 It connects with R to form a 4 or 5-membered ring. In some embodiments, R 4 Equation (XII): [ka] (In the formula, m is either 0 or 1. n is either 0 or 1. p is 0, 1, or 2. or a pharmaceutically acceptable salt thereof.

[0093] In some embodiments, R 4 Equation (XVII): [ka] (In the formula, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, m is either 1 or 2. n is either 0 or 1. z is either 1 or 2. That is the case.

[0094] In some embodiments, R 4 Equation (XVIII): [ka] (In the formula, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, m is either 1 or 2. That is the case.

[0095] In some embodiments, X 9 is a bond. In some embodiments, X 9 is -N(R 29 )-. In some embodiments, R 29 It is CH3.

[0096] In some embodiments, X 11 is -O-. In some embodiments, X 11 is C 1~3 It is an alkanedyl. In some embodiments, X 11 is -CH2-. In some embodiments, X 11 is -N(R 30 )-. In some embodiments, R 30 It is CH3.

[0097] In some embodiments, R 4 is given by equation (XII), where if m is 0, then p is 1 or 2. In some embodiments, R 4 is given by equation (XII), where if p is 2, then m is 0. In some embodiments, R 4 is given by equation (XII), where if m is 0, p is 1 or 2, and if p is 2, m is 0. In some embodiments, R 4 The equation is (XII) (wherein m is 0 or 1, n is 0 or 1, and p is 0, 1 or 2, except when m is 0, p is 1 or 2, and when p is 2, m is 0).

[0098] In some embodiments, m is 0. In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, p is 0. In some embodiments, p is 1. In some embodiments, p is 2. In some embodiments, m is 0 and p is 1. In some embodiments, m is 1 and p is 1. In some embodiments, m is 1 and p is 0. In some embodiments, m is 0 and p is 2. In some embodiments, n is 0. In some embodiments, n is 1. In some embodiments, z is 1. In some embodiments, z is 2. In some embodiments, n is 1 and z is 1. In some embodiments, n is 1 and z is 2. In some embodiments, n is 0 and z is 2.

[0099] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is equation (XIX): [ka] (In the formula, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 10 is -C(O)-, -CH2-, or a bond, X 11 is -O-, -CH2-, or -N(R 30 )- and, R30 is C 1~3 It is alkyl, X 12 is -N(C(O)R 24 )- or combination, m is either 1 or 2. n is either 0 or 1. z is either 1 or 2, However, X 10 If X is -C(O)-, 12 It is a combination, However, X 10 If it is a -CH2- or bond, X 12 is -N(C(O)R 24 This relates to compounds of (where ring A is a 4-6 membered ring) or pharmaceutically acceptable salts thereof.

[0100] In some embodiments, ring A is a four-membered ring. In some embodiments, ring A is a five-membered ring.

[0101] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and R 11 R 9 It connects with the intervening atom to form a ring. In some embodiments, R 11 is R 9 It connects with X to form a 6-membered ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and R 11 R 9 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 R 9 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 is R 9 It connects with R to form a 6-membered ring. In some embodiments, R 4 Equation (LI): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 11 is -O-, -N(R 28)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0102] In some embodiments, R 4 is equation (LIa): [ka] (In the formula, R 7 , R 8 , R 9 , R 10 , R 11 , R 17 , R 18 , R 19 , and R 20 (as defined herein). In some embodiments, the part of formula (LI) is formula (Lia).

[0103] In some embodiments, R 4 is equation (LI) or equation (LIa), and R 7 , R 8 , R 10 , R17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 4 is equation (LI) or equation (LIa), and R 11 is -O-. In some embodiments, R 4 is equation (LI) or equation (LIa), and R 11 is -CH2-. In some embodiments, R 4 is equation (LI) or equation (LIa), and R 11 It is -CH2CH2-.

[0104] In some embodiments, R 11 is R 9 It connects to form a ring, R 9 C may be bonded or substituted with 1 to 3 Fs. 1~3 It is Alkandil, R 10 H is H, R 11 is C 1~3 It is an alkanediyl, where one methylene group is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl.

[0105] In some embodiments, R 11 is R 9 It connects with the others to form a five-membered ring.

[0106] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and R 11 R 10 It connects with the intervening atom to form a ring. In some embodiments, R 11 is R 10 It connects with X to form a 6-membered ring. In some embodiments, X 2 is C(R 9 )(R10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and R 11 R 10 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 R 10 It connects with the intervening atom to form a ring. In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 is R 10 It connects with R to form a 6-membered ring. In some embodiments, R 4 is equation (LII): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3Alkyl or halogen such as F, R 10 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 (Alkyl, or halogen such as fluorine) That is the case.

[0107] In some embodiments, R 4 is equation (LIIa): [ka] (In the formula, R 7 , R 8 , R 9 , R10 , R 11 , R 17 , R 18 , R 19 , and R 20 (as defined herein). In some embodiments, the part of formula (LII) is formula (LIIa).

[0108] In some embodiments, R 4 is equation (LII) or equation (LIIa), and R 7 , R 8 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 4 is equation (LII) or equation (LIIa), and R 11 is -O-. In some embodiments, R 4 is equation (LII) or equation (LIIa), and R 11 is -CH2-. In some embodiments, R 4 is equation (LII) or equation (LIIa), and R 11 It is -CH2CH2-.

[0109] In some embodiments, R 11 is R 10 It connects to form a ring, R 9 H is H, R 10 C may be bonded or substituted with 1 to 3 Fs. 1~3 It is Alkandil, R 11 is C 1~3 It is an alkanediyl, where one methylene group is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl.

[0110] In some embodiments, R 11 is R 10 It connects with the others to form a five-membered ring.

[0111] In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -O-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl. 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -CH2-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -CH2CH2-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -CH2O-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -N(R 28)-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -N(CH3)-. In some embodiments, R 11 R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 is -O-. In some embodiments, R 11 R 9 It connects with the intervening atom and forms a ring, R 11 -R 9 These are -(CH2)3-, -(CH2)O-, -(CH2)2O-, -CH2OCH2-, -C(H)(CH3)CH2-, and -C(O)N(H)-. In some embodiments, R 11 R 10 It connects with the intervening atom and forms a ring, R 11 -R 10 These are -(CH2)3-, -(CH2)O-, -(CH2)2O-, -CH2OCH2-, -C(H)(CH3)CH2-, and -C(O)N(H)-.

[0112] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 is R 9 It connects with R to form a 5-membered ring. In some embodiments, R 4 is equation (XX): [ka] (In the formula, R 7 H, 1-3 F or C 1~3C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 -CH2-, -O-, -CH2O-, -OCH2-, -N(R 28 )-, or -CH2N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) That is the case.

[0113] In some embodiments, the part of formula (XX) is formula (XXa): [ka] That is the case.

[0114] In some embodiments, R 4 is equation (XXa) (where, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) That is the case.

[0115] In some embodiments, X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R18 ) and X 5 is C(R 19 )(R 20 ) and X 6 It is a bond, R 11 is R 10 It connects with the others to form a five-membered ring.

[0116] In some embodiments, the part of formula (XX) is formula (XXb): [ka] That is the case.

[0117] In some embodiments, R 4 is equation (XXb) (where, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) That is the case.

[0118] In one embodiment, the present invention relates to formula (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is equation (XXa) or equation (XXb): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) (is) This relates to the compound or its pharmaceutically acceptable salt.

[0119] In some embodiments, R 4 is equation (XXa), and R 7 , R 8 , R 10 , R 17 , R 18 , R 19 , and R 20 is H. In some embodiments, R 4 Equation (XXb) is given by R 7 , R 8 , R 9 , R 17 , R 18 , R 19 , and R 20 H is H.

[0120] In some embodiments, R 4 Equation (XV): [ka] (In the formula, X8 is -CH2-, -O- or -N(R 28 )- and R 28 is H or C 1~3 It is alkyl.

[0121] In one embodiment, the present invention relates to formula (XXIII): [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) This relates to the compound or its pharmaceutically acceptable salt.

[0122] In some embodiments, X 8 is -CH2-. In some embodiments, X 8 is -O-. In some embodiments, X 8 is -N(R 28 )-. In some embodiments, X 8 is -CH2O-. In some embodiments, X 8 is -OCH2-. In some embodiments, X 8 -CH2N(R 28 )-. In some embodiments, R 28 is C 1~3 It is alkyl. In some embodiments, R 28 is CH3. In some embodiments, X 8 It is -N(CH3)-.

[0123] In some embodiments, R 7 is H. In some embodiments, R 7 is C 1~3 It is alkyl. In some embodiments, R 7 is CH3. In some embodiments, R 7 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 7 C 1~3 C substituted with alkoxy 1~3 It is alkyl. In some embodiments, R 7 is CH2OCH3. In some embodiments, R 7 These are halogens such as F.

[0124] In some embodiments, R 8 is H. In some embodiments, R 8 is C 1~3 It is alkyl. In some embodiments, R 8 is CH3. In some embodiments, R 8 C 1~3 C substituted with alkoxy 1~3 It is alkyl. In some embodiments, R 8 is CH2OCH3. In some embodiments, R 8 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 8 These are halogens such as F.

[0125] In some embodiments, R 9 is H. In some embodiments, R 9 is C 1~3 It is alkyl. In some embodiments, R 9 C is replaced by 1 to 3 halogens. 1~3 It is alkyl. In some embodiments, R 9 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 9 is -C(O)N(R 31 )(R 32 ) and here, R31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 It is alkyl. In some embodiments, R 9 is -C(O)N(H)(CH3). In some embodiments, R 9 is -C(O)NH2. In some embodiments, R 9 is -C(O)N(CH3)2. In some embodiments, R 9 is a halogen such as F. In some embodiments, R 9 is R 11 It connects to form a ring, R 9 is a bond. In some embodiments, R 9 is R 11 It connects to form a ring, R 9 is -C(O)-. In some embodiments, R 9 is R 11 It connects to form a ring, R 9 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl. 9 is R 11 It connects to form a ring, R 9 is -CH2-. In some embodiments, R 9 is R 11 It connects to form a ring, R 9 is -(CH2)2-. In some embodiments, R 9 is R 11 It connects to form a ring, R 9 is -C(H)(CH3)-. In some embodiments, R 9 is R 11 or R 13 It connects to form a ring, R 9 is a bond. In some embodiments, R 9 is R 11 or R 13 It connects to form a ring, R 9 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3It is an alkanedyl. 9 is R 11 or R 13 It connects to form a ring, R 9 is -CH2-. In some embodiments, R 9 is R 11 or R 13 It connects to form a ring, R 9 It is -CH2CH2-.

[0126] In some embodiments, R 31 is H. In some embodiments, R 31 is C 1~3 It is alkyl. In some embodiments, R 31 is CH3. In some embodiments, R 32 is H. In some embodiments, R 32 is C 1~3 It is alkyl. In some embodiments, R 32 It is CH3.

[0127] In some embodiments, R 10 is H. In some embodiments, R 10 is C 1~3 It is alkyl. In some embodiments, R 10 C is replaced by 1 to 3 halogens. 1~3 It is alkyl. In some embodiments, R 10 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 10 is -C(O)N(R 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 It is alkyl. In some embodiments, R 10 is -C(O)N(H)(CH3). In some embodiments, R 10 is -C(O)NH2. In some embodiments, R 10 is -C(O)N(CH3)2. In some embodiments, R 10is a halogen such as F. In some embodiments, R 10 is R 11 It connects to form a ring, R 9 is a bond. In some embodiments, R 10 is R 11 It connects to form a ring, R 9 is -C(O)-. In some embodiments, R 10 is R 11 It connects to form a ring, R 9 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl. 10 is R 11 It connects to form a ring, R 9 is -CH2-. In some embodiments, R 10 is R 11 It connects to form a ring, R 9 is -(CH2)2-. In some embodiments, R 10 is R 11 It connects to form a ring, R 9 is -C(H)(CH3)-. In some embodiments, R 10 is R 11 or R 13 It connects to form a ring, R 10 is a bond. In some embodiments, R 10 is R 11 or R 13 It connects to form a ring, R 10 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl. 10 is R 11 or R 13 It connects to form a ring, R 10 is -CH2-. In some embodiments, R 10 is R 11 or R 13 It connects to form a ring, R 10 It is -CH2CH2-.

[0128] In some embodiments, X 13 is a bond. Therefore, in one embodiment, R 11 is R 33 In some embodiments, X 13 is C 1~3 It is an alkanedyl. In some embodiments, X 13 is -CH2-. In some embodiments, X 13 C 1~3 C substituted with alkyl 1~3 It is an alkanedyl. In some embodiments, X 13 is -C(H)(CH3)-. In some embodiments, X 13 is -O-. In some embodiments, X 13 is -C 1~3 It is an alkanediyl-O-. In some embodiments, X 13 is -CH2O-. In some embodiments, X 13 is a bond, -CH2-, -C(H)(CH3)-, -O-, or -CH2O-. In some embodiments, X 13 is -O- or -C 1~3 If it is an alkanediyl-O-, then R 33 is R 33 X via carbon atoms 13 It connects to this.

[0129] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 Azetidinyl may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 33 is azetidinil. In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 is azetidinil. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 is halogen, C 1~3 Alkoxy, and C 1~3 Azetidinyl which may be substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 is halogen, C 1~3 Azetidinyl which may be substituted with one or more substituents selected from alkyl and NH2. In some embodiments, R 11 is halogen, and C 1~3 It is an azetidinyl substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 is an azetidinyl substituted with a halogen such as F. In some embodiments, R 33 This is a halogen(s) that is one or more substituents and / or one or more C 1~3 It is an alkyl-substituted azetidinyl. In some embodiments, R 33 is an azetidinyl substituted with one or more halogens. In some embodiments, R 33 is an azetidinyl substituted with one or more F. In some embodiments, R 33 is an azetidinyl substituted with one or two F. In some embodiments, R 11teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 C 1~3 It is an azetidinyl substituted with an alkoxy. In some embodiments, R 33 is an azetidinyl substituted with -OCH3. In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11C is substituted with -O-azetidinyl. 1~3 It is alkyl, where azetidinyl may be substituted with CH3. In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 CH3 and other C 1~3 It is an alkyl-substituted azetidinyl. In some embodiments, R 11 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 C 1~3 It is an azetidinyl which may be substituted with alkyl. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0130] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 The oxetanyl may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 33 is oxetanyl. In some embodiments, R 33 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 is oxetanyl. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 is one or more C 1~3 It is an alkyl-substituted oxetanyl. In some embodiments, R 33 is an oxetanyl substituted with one or more -CH3 groups. In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0131] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 The pyrrolidinyl may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 The pyrrolidinyl may be substituted with one or more substituents individually selected from alkyl groups.

[0132] In some embodiments, R 33 is a pyrrolidinyl substituted with one or more F. In some embodiments, R 33 This may be replaced by one or more Fs, or one or more Cs. 1~3 It is a pyrrolidinyl that is alkyl-substituted. In some embodiments, R 33 is a pyrrolidinyl substituted with one or more -CH3 groups. In some embodiments, R 33 is a pyrrolidinyl substituted with one or more -CF3 groups. In some embodiments, R 11 C 1~3 Alkyl, halogen, C 1~3 Alkoxy, C 1~3 The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of haloalkyl, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. In some embodiments, R 33 Equation (XIV): [ka] (In the formula, R 25 is H or C 1~3 It is alkyl, R 26 These are, individually, halogens such as F, C 1~3 Alkyl, or C such as CF3 1~3 It is a haloalkyl (where q is 0, 1, or 2). In some embodiments, R 11 Equation (XIV): [ka] (In the formula, R25 is H or C 1~3 is alkyl, and R 26 is, individually, a halogen such as F, C 1~3 alkyl, or C such as CF3 1~3 haloalkyl, and q is 0, 1, or 2). In some embodiments, R 11 is pyrrolidinyl optionally substituted with one or more substituents individually selected from C 1~3 alkyl and halogen. In some embodiments, R 11 is of formula (XIV) (wherein R 25 is H or C 1~3 alkyl, and R 26 is a halogen such as F, or C 1~3 alkyl, and q is 0, 1, or 2). In some embodiments, q is 0. In some embodiments, q is 1. In some embodiments, R 33 is of formula (XIVa) or formula (XIVb):

Chemical formula

[0133] In some embodiments, q is 2. In some embodiments, R 11 is of formula (XIVa) (wherein R 25 is H or C 1~3 alkyl, and R 26a is H or F, and R 26b is H or F). In some embodiments, the moiety of formula (XIVa) is of formula (XIVa-1) or formula (XIVa-2):

Chemical formula

[0134] In some embodiments, R 11 is of formula (XIVa-1) (wherein R25 is H or C 1~3 It is alkyl, R 26a is H or F, R 26b (is H or F). In some embodiments, R 11 is equation (XIVa-2) (where R 25 is H or C 1~3 It is alkyl, R 26a is H or F, R 26b (is H or F).

[0135] In some embodiments, R 26a is F. In some embodiments, R 26b is F. In some embodiments, R 26a F is R 26b is F. In some embodiments, R 26a F is R 26b is H. In some embodiments, R 26a H is R 26b It is F.

[0136] In some embodiments, R 11 is equation (XIVb) (where R 25 is H or C 1~3 (It is alkyl). In some embodiments, the (XIVb) part is formula (XIVb-1) or formula (XIVb-2): [ka] That is the case.

[0137] In some embodiments, R 11 is equation (XIVb-1) (where R 25 is H or C 1~3 It is alkyl. In some embodiments, R 11 is equation (XIVb-2) (where R 25 is H or C 1~3 It is alkyl.

[0138] In some embodiments, R 25 is H. In some embodiments, R 25is C 1~3 is alkyl. In some embodiments, R 25 is CH3.

[0139] In some embodiments, R 33 is

Chemical formula

Chemical formula

Chemical formula

[0140] In some embodiments, R 11 is pyrrolidinyl. In some embodiments, R 11 is

Chemical formula

Chemical formula

Chemical formula

Chemical formula

Chemical formula

Chemical formula

[0141] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 Tetrahydrofuranyl which may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 33 is tetrahydrofuranil. In some embodiments, R 11 is tetrahydrofuranil. In some embodiments, R 33 is tetrahydrofuran-2-yl. In some embodiments, R 33 teeth [ka] In some embodiments, R 11 is tetrahydrofuran-2-yl. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0142] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 Morpholinyl may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 33 It is morpholinyl.

[0143] In some embodiments, R33 This is N-morpholinyl.

[0144] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 C 1~3 Morpholinyl may be substituted with alkyl. In some embodiments, R 11 is morpholinyl. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 C 1~3 It is an alkyl-substituted morpholinyl. In some embodiments, R 11 This is morpholinyl substituted with CH3. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0145] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 The pyridinyl may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 33is a pyridinyl which may be substituted with one or more NH2 groups. In some embodiments, R 33 is a pyridinyl substituted with NH2. In some embodiments, R 33 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 is a pyridinyl which may be substituted with one or more NH2 groups. In some embodiments, R 11 is a pyridinyl substituted with NH2. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0146] In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 C may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. 1~3It is alkyl. In some embodiments, R 11 is NH2, N(H)(CH3), N(CH3)2, C 1~3 C may be substituted with one or more substituents individually selected from the group consisting of alkoxy, morpholinyl, azetidinyl, -O-azetidinyl, and -O-oxetanyl. 1~3 It is an alkyl group, and the azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 are NH2, N(CH3)2, N(H)(CH3), C 1~3 C may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. 1~3 It is alkyl. In some embodiments, R 11 These are NH2, N(CH3)2, N(H)(CH3) and C 1~3 C may be substituted with one or more substituents individually selected from the group consisting of alkoxys. 1~3 It is alkyl.

[0147] In some embodiments, R 33 is C 1~3 It is alkyl. In some embodiments, R 33 is CH3. In some embodiments, R 11 is C 1~3 It is alkyl. In some embodiments, R 11 is CH3. In some embodiments, R 33 is NH2. In some embodiments, R 33 is N(H)(CH3). In some embodiments, R 33 is N(CH3)2. In some embodiments, R 11 C is a C that is substituted with one or more N(CH3)2 atoms. 1~3 It is alkyl. In some embodiments, R 11 C is substituted with one or more NH2 molecules. 1~3 It is alkyl. In some embodiments, R 11is -CH2NH2. In some embodiments, R 11 C is a C that is substituted with one or more N(CH3)2 atoms. 1~3 It is alkyl. In some embodiments, R 11 is -CH2N(CH3)2. In some embodiments, R 11 is -CH2-N(H)(CH3). In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3 C may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. 1~3 It is an alkoxy. In some embodiments, R 33 is C 1~3 It is an alkoxy. In some embodiments, R 33 is -OCH3. In some embodiments, R 11 is one or more C 1~3 C substituted with alkoxy 1~3 It is alkyl. In some embodiments, R 11 is -CH2OCH3. In some embodiments, R 11 is C 1~3 It is an alkoxy. In some embodiments, R 11 is -OCH3. In some embodiments, R 33 C may be replaced by one or more Fs. 1~3 It is alkyl. In some embodiments, R 33 is CF3. In some embodiments, R 33 is CHF2. In some embodiments, R 11 is -CH2-O-CF3. In some embodiments, R 11 is -CH2-O-CHF2. In some embodiments, R 11 is CHF2. In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 C which may be substituted with alkoxy or one or more F atoms. 1~3C may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. 3~6 It is cycloalkyl. In some embodiments, R 33 is C 3~6 It is cycloalkyl. In some embodiments, R 33 C may be replaced by a halogen, one or more Fs. 1~3 Alkoxy and C which may be substituted with one or more F 1~3 C is substituted with one or more substituents individually selected from alkyl groups. 3~6 It is cycloalkyl. In some embodiments, R 33 is halogen, and C 1~3 C is substituted with one or more substituents selected from alkoxys. 3~6 It is cycloalkyl. In some embodiments, R 33 C is replaced by one or more Fs. 3~6 It is cycloalkyl. In some embodiments, R 11 C 1~3 C substituted with alkoxy 3~6 It is cycloalkyl. In some embodiments, R 11 C is substituted with -OCH3. 3~6 It is cycloalkyl. In some embodiments, C 3~6 Cycloalkyl is C 3~5 It is cycloalkyl. In some embodiments, C 3~5 The cycloalkyl is cyclobutyl. In some embodiments, R 33 teeth [ka] In some embodiments, R 33 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] In some embodiments, R 33 is C 3~6 It is cycloalkyl. In some embodiments, R 33 is cyclopropyl. In some embodiments, R 11 is C 3~5 It is cycloalkyl. In some embodiments, R 11 is cyclopropyl. In some embodiments, R 11 C is substituted with morpholinyl. 1~3 It is alkyl. In some embodiments, R 11 is a C1 alkyl group substituted with morpholinyl. In some embodiments, R 11 C is substituted with azetidinyl. 1~3 It is an alkyl group, where azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 This is a C1 alkyl substituted with azetidinyl, where azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 C is substituted with azetidinyl. 1~3 It is alkyl. In some embodiments, R 11 C is substituted with azetidinyl. 1~3 It is an alkyl group, where azetidinyl is substituted with one or more halogens. In some embodiments, R 11 C is substituted with azetidinyl. 1~3 It is alkyl, where azetidinyl is substituted with one or more F. In some embodiments, R 11 C is substituted with azetidinyl. 1~3It is alkyl, where azetidinyl is substituted with one or two F. In some embodiments, R 11 C is substituted with -O-azetidinyl. 1~3 It is an alkyl group, where azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. In some embodiments, R 11 C is substituted with -O-azetidinyl. 1~3 It is alkyl. In some embodiments, R 11 C is substituted with -O-azetidinyl. 1~3 It is alkyl, and here azetidinyl is C 1~3 It may be substituted with alkyl. In some embodiments, R 11 C is substituted with -O-azetidinyl. 1~3 It is alkyl, where azetidinyl may be substituted with CH3. In some embodiments, R 11 C is substituted with -O-oxetanyl 1~3 It is alkyl.

[0148] In some embodiments, R 11 is halogen, and C 1~3 C may be substituted with one or more substituents selected from alkoxys. 3~5 It is cycloalkyl. In some embodiments, R 11 C may be substituted with one or more halogens such as F. 3~5 It is cycloalkyl. In some embodiments, R 11 C such as -OCH3 1~3 C may be substituted with alkoxy. 3~5 It is cycloalkyl. In some embodiments, C 3~5 The cycloalkyl is cyclobutyl. In some embodiments, R 11 teeth [ka] In some embodiments, R 11 teeth [ka] That is the case.

[0149] In some embodiments, R 12 is H. In some embodiments, R 12 is C 1~3 It is alkyl. In some embodiments, R 12 It is CH3.

[0150] In some embodiments, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The azetidinyl may be substituted with NH2.

[0151] In some embodiments, R 13 is N(H)(CH3). In some embodiments, R 13 If is pyrrolidinyl, azetidinyl, or piperazinyl, then the pyrrolidinyl, azetidinyl, or piperazinyl is bound to the rest of the molecule via the N atom in the pyrrolidinyl, azetidinyl, or piperazinyl. In some embodiments, R 13 This is a pyrrolidinyl which may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. In some embodiments, R 13 is a pyrrolidinyl which may be substituted with NH2, N(H)(CH3), or N(CH3)2. In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 This is a pyrrolidinyl substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), and N(CH3)2. In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 is piperazinyl. In some embodiments, R 13 teeth [ka] In some embodiments, R 13 is a pyrrolidinyl which may be substituted with azetidinyl, and the azetidinyl may be substituted with one or more halogens. In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 teeth [ka] In some embodiments, R 13 is an azetidinyl which may be substituted with NH2. In some embodiments, R 13 teeth [ka] In some embodiments, R 13 is NH2, N(H)(CH3), or N(CH3)2. In some embodiments, R 13 R 9 , R 10 , R 17 , or R 18 It connects with the intervening atom and forms a ring, R 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl. In some embodiments, R 13 It is -N(CH3)-.

[0152] In some embodiments, R 14 It is N(H)(C(O)CH3).

[0153] In some embodiments, R 15 H is H.

[0154] In some embodiments, R 16 is H. In some embodiments, R 16 is C 1~3 It is alkyl. In some embodiments, R 16 It is CH3.

[0155] In some embodiments, R17 is H. In some embodiments, R 17 is C 1~3 It is alkyl. In some embodiments, R 17 is CH3. In some embodiments, R 17 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 17 These are halogens such as F.

[0156] In some embodiments, R 18 is H. In some embodiments, R 18 is C 1~3 It is alkyl. In some embodiments, R 18 is CH3. In some embodiments, R 18 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 18 These are halogens such as F.

[0157] In some embodiments, R 19 is H. In some embodiments, R 19 is C 1~3 It is alkyl. In some embodiments, R 19 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 19 These are halogens such as F.

[0158] In some embodiments, R 20 is H. In some embodiments, R 20 is C 1~3 It is alkyl. In some embodiments, R 20 is CH3. In some embodiments, R 20 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 20 These are halogens such as F.

[0159] In some embodiments, R 21 is H. In some embodiments, R 21 is C1~3 It is alkyl. In some embodiments, R 21 is CH3. In some embodiments, R 21 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 21 These are halogens such as F.

[0160] In some embodiments, R 22 is H. In some embodiments, R 22 is C 1~3 It is alkyl. In some embodiments, R 22 is CH3. In some embodiments, R 22 C is substituted with 1 to 3 Fs. 1~3 It is alkyl. In some embodiments, R 22 These are halogens such as F.

[0161] In some embodiments, R 23 is H. In some embodiments, R 23 is C 1~3 It is alkyl. In some embodiments, R 23 It is a bond, R 15 is C 1~3 It is an alkanedyl, R 23 is R 15 It connects with the others to form a 4- or 5-membered ring.

[0162] In some embodiments, R 24 It is CH3.

[0163] In some embodiments, X 2 , X 5 and X 6 Two or fewer of these are combinations.

[0164] In some embodiments, azetidinyl is azetidine-1-yl. In some embodiments, azetidinyl is azetidine-2-yl. In some embodiments, azetidinyl is azetidine-3-yl. In some embodiments, morpholinyl is morpholin-4-yl.

[0165] In some embodiments, morpholinyl is morpholin-3-yl. In some embodiments, pyrrolidinyl is pyrrolidin-1-yl.

[0166] In some embodiments, pyrrolidinyl is pyrrolidin-2-yl. In some embodiments, pyrrolidinyl is pyrrolidin-3-yl.

[0167] In some embodiments, oxetanyl is oxetan-2-yl. In some embodiments, oxetanyl is oxetan-3-yl.

[0168] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0169] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] is. In some embodiments, R 4 is

Chemical formula

Chemical formula

Chemical formula

Chemical formula

Chemical formula

[0170] In some embodiments, R 4 is

Chemical formula

Chemical formula

Chemical formula

[0171] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0172] In some embodiments, R 4 teeth [ka] That is. R 4 but [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0173] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0174] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0175] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0176] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0177] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0178] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0179] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] In some embodiments, R 4 teeth [ka] That is the case.

[0180] In some embodiments, the compound is (3aR,7aR)-2-[(4-fluoro-1H-indole-2-yl)carbonyl]hexahydropyrano[3,4-c]pyrrole-7a(1H)-carboxamide, (4,5-Dichloro-1H-Indole-2-yl)(3-(Pyrrolidine-1-carbonyl)piperidine-1-yl)methanone, (4aR,7aS)-1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]octahydro-5H-pyrrolo[3,4-b]pyridine-5-one, (4-Chloro-1H-indole-2-yl)(4-(cyclobutancarbonyl)piperazine-1-yl)methanone, (4-Chloro-5-methyl-1H-indole-2-yl)(4-(cyclopropanecarbonyl)-2,2-dimethylpiperazine-1-yl)methanone, (4-Fluoro-1H-Indole-2-yl)(3-(Pyrrolidine-1-carbonyl)piperidine-1-yl)methanone, [2-(cyclopropylcarbonyl)-4-morpholinyl](4,5-dichloro-1H-indole-2-yl)-methanone, [2-(cyclopropylcarbonyl)-4-morpholinyl](4-fluoro-1H-indole-2-yl)-methanone, [4-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]-2-morpholinyl]cyclopropyl-methanone, 1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3-methyl-3-pyrrolidinecarboxamide, 1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3-piperidinecarboxamide, 1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3-pyrrolidinecarboxamide, 1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-N-methyl-3-piperidinecarboxamide, 1-[(4-bromo-1H-indole-2-yl)carbonyl]-3-methyl-3-pyrrolidinecarboxamide, 1-[(4-bromo-1H-indole-2-yl)carbonyl]-3-piperidinecarboxamide, 1-[(4-bromo-1H-indole-2-yl)carbonyl]-N-methyl-3-piperidinecarboxamide, 1-[(4-fluoro-1H-indole-2-yl)carbonyl]-N-methyl-3-piperidinecarboxamide, 1-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]-3-methyl-3-pyrrolidinecarboxamide, 1-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]-3-piperidinecarboxamide, 1-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]-N-methyl-3-piperidinecarboxamide, 1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]-2,2-dimethyl-1-propanone, 1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]-2-methoxyethanone, 1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]-2-methyl-1-propanone, 1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]ethanone, 1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3,3-dimethyl-1-piperazinyl]ethanone, 1-[4-[(4-chloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]ethanone, 2-[(4,5-dichloro-1H-indole-2-yl)carbonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-[(4,5-dichloro-1H-indole-2-yl)carbonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-[(4-bromo-1H-indole-2-yl)carbonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-[(4-chloro-1H-indole-2-yl)carbonyl]-7-(2-hydroxyethyl)-2,7-diazaspiro[4.5]decane-6-one, 2-[(4-fluoro-1H-indole-2-yl)carbonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-amino-1-[4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-piperazinyl]-ethanone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1-(1-methylethyl)-2-piperazinone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-1,6-dimethyl-2-piperazinone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-2-piperazinone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3,3-dimethyl-2-piperazinone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-3-propyl-2-piperazinone, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-N-methyl-2-morpholinecarboxamide, 4-[(4,5-dichloro-1H-indole-2-yl)carbonyl]octahydro-2(1H)-quinoxalinone, 7-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-2,7-diazaspiro[4.4]nonane-3-one, 7-[(4,5-dichloro-1H-indole-2-yl)carbonyl]hexahydroimidazo[1,5-a]pyrazine-3(2H)-one, 7-[(4-chloro-1H-indole-2-yl)carbonyl]hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, 7-[(4-chloro-5-fluoro-1H-indole-2-yl)carbonyl]-2,7-diazaspiro[4.4]nonane-3-one, rel-(3aR,7aR)-2-[(4-fluoro-1H-indole-2-yl)carbonyl]hexahydropyrano[3,4-c]pyrrole-7a(1H)-carboxamide, rel-(3R,4R)-1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-4-methyl-3-pyrrolidinecarboxamide, rel-(3R,4R)-1-[(4-bromo-1H-indole-2-yl)carbonyl]-4-methyl-3-pyrrolidinecarboxamide, and rel-(3R,4R)-1-[(6-bromo-4-fluoro-1H-indole-2-yl)carbonyl]-4-methyl-3-pyrrolidinecarboxamide It is not a compound selected from the group consisting of the following.

[0181] In some embodiments, the compound is [ka] Selected from group A consisting of JPEG2026526087000346.jpg201159JPEG2026526087000347.jpg193159JPEG2026526087000348.jpg192159JPEG2026526087000349.jpg193159JPEG2026526087000350.jpg186159JPEG2026526087000351.jpg190159JPEG2026526087000352.jpg178159JPEG2026526087000353.jpg69159, or from pharmaceutically acceptable salts thereof.

[0182] In one embodiment, the present invention relates to a compound selected from group A or a pharmaceutically acceptable salt thereof.

[0183] In some embodiments, the compound is 4-(3,4,5-trichloro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[(2R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methyl-piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. 1-[(2S)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methyl-piperazine-1-yl]ethanone. In some embodiments, the compound is 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)-2,2-dimethyl-piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[(3S)-4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methyl-piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[(3R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methyl-piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[3-(4,5-dichloro-1H-indole-2-carbonyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]etanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3S)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 4-(4,5-dichloro-1H-indole-2-carbonyl)-1-methylpiperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]etanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4,5-dichloro-6-fluoro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3R)-1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-N-methylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3S)-1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-N-methylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4-chloro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]-2-methoxy-ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]-2-(dimethylamino)ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]-2-methoxyethanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 4-(4,5-dichloro-7-fluoro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4,5-dichloro-3-fluoro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4,5-dichloro-1H-indole-2-yl)(4-(pyrroridine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4,5-dichloro-1H-indole-2-yl)(4-(pyrroridine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-amino-1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [4-(azetidine-3-carbonyl)piperazine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4,5-dichloro-1H-indole-2-yl)-[4-[(3R)-pyrrolidine-3-carbonyl]piperazine-1-yl]methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4,5-dichloro-1H-indole-2-yl)-[4-[(3S)-pyrrolidine-3-carbonyl]piperazine-1-yl]methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [4-[(2S)-azetidine-2-carbonyl]piperazin-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (4,5-dichloro-1H-indole-2-yl)-[4-[(2S)-pyrrolidine-2-carbonyl]piperazine-1-yl]methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4,5-dichloro-1H-indole-2-yl)-[4-[(2R)-pyrrolidine-2-carbonyl]piperazine-1-yl]methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-amino-1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-(cyclopropanecarbonyl)piperazine-1-yl)(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((S)-3-aminopyrrolidine-1-yl)((S)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((S)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((S)-3-aminopyrrolidine-1-yl)((R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [(3R)-3-(3-aminoazetidine-1-carbonyl)pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is [(3S)-3-(3-aminoazetidine-1-carbonyl)pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [(3R)-3-[(3S)-3-aminopyrrolidine-1-carbonyl]pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [(3S)-3-[(3R)-3-aminopyrrolidine-1-carbonyl]pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [(3R)-3-[(3R)-3-aminopyrrolidine-1-carbonyl]pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is [(3S)-3-[(3S)-3-aminopyrrolidine-1-carbonyl]pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is N-[1-(4-acetamidophenyl)sulfonyl-4-piperidyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-N-(1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)acetamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-N-(1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)acetamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is me. The compound is 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4,5-dichloro-1H-indole-2-carbonyl)-N-methylmorpholine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3,3-dimethylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrroridine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (S)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(3-(4,5-dichloro-1H-indole-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(5-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-((2S,5R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-dimethylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-((2R,5S)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-dimethylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-((2S,5S)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-dimethylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-((2R,5R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-dimethylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4,5-dichloro-1H-indole-2-carbonyl)-N,N-dimethylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (S)-1-(4,5-dichloro-1H-indole-2-carbonyl)-N,N-dimethylpyrrolidine-3-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(8-(4,5-dichloro-1H-indole-2-carbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,5-dimethylpiperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,5-dimethylpiperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-amino-1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-amino-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-(4,5-dichloro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4,5-dichloro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-azetidine-2-yl(4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-azetidine-2-yl(4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((S)-3-aminopyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3S)-3-(3-(dimethylamino)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((S)-3-aminopyrrolidine-1-yl)((S)-1-(4-chloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((S)-1-(4-chloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((S)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3-(azetidine-1-yl)pyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3-(azetidine-1-yl)pyrrolidine-1-yl)((S)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3S)-3-(3-(3,3-difluoroazetidine-1-yl)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (2-amino-4-pyridyl)-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-2,6-diazaspiro[3.4]octan-2-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-1,6-diazaspiro[3.4]octan-1-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(7-(4,5-dichloro-1H-indole-2-carbonyl)-1,7-diazaspiro[4.4]nonan-1-yl)ethane-1-one, and also. is a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(2-(4,5-dichloro-1H-indole-2-carbonyl)-2,6-diazaspiro[3.4]octan-6-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(7-(4,5-dichloro-1H-indole-2-carbonyl)-2,7-diazaspiro[4.4]nonane-2-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyl-2,8-diazaspiro[4.5]decane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-1,8-diazaspiro[4.5]decan-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethyl-1,3,8-triazaspiro[4.5]decan-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethylpiperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethylpiperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidin-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(pyrroridine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoropyrroridine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidin-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydroimidazo[1,5-a]pyrazine-3(2H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidin-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(1-methylpyrrolidine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(1-methylpyrrolidine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (4-(6-aminonicotinoyl)piperazin-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-(2-aminoisonicotinoyl)piperazin-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazin-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4,5-dichloro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-amino-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((3S,4R)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((3S,4S)-4-(trifluoromethyl)pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is azetidine-3-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoroazetidine-3-carbonyl)piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is ((3S,4S)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4-chloro-3,5-difluoro-1H-indole-2-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 2-(azetidine-3-yloxy)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, or its pharmaceutically acceptable form. It is a pharmaceutically acceptable salt. In some embodiments, the compound is 1-(4-(3-chloro-4-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-2-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetane-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3,3-difluorocyclobutan-1-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-((1R,3R)-3-methoxycyclobutan-1-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3-chloro-4,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetane-2-carbonyl)piperazin-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(azetidine-1-yl)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(1-methylazetidine-3-carbonyl)piperazin-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3aR,6aR)-5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-L-prolyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 2-(azetidine-1-yl)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-6H-pyrido[1,2-a]pyrazine-6-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(oxetane-3-yloxy)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoropyrroridine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyloctahydro-3H-pyrrolo[3,4-c]pyridine-3-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoro-1-methylazetidine-3-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3-fluoroazetidine-3-yl)methyl 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(oxetane-3-yloxy)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-8-methylhexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(a. The compound is zethidine-3-yloxy)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3aR,6aR)-5-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (3aS,6aS)-5-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one, or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-3-yl)ethane-1-one, or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoropyrrolidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluorocyclobutoxy)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-(methoxymethyl)piperazin-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylmorpholine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazin-4(3H)-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazin-1-yl)-2,2-difluoroethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(2-methyloxetane-2-carbonyl)piperazin-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(2-methyloxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(trifluoromethoxy)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(difluoromethoxy)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N-methylpiperazine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N-methylpiperazine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (R)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(oxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-1H-indole-2-yl)(4-(oxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S)-(3,4-dichloro-1H-indole-2-yl)(4-(oxetane-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof.In some embodiments, the compound is (S)-1-(4-(3,4-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-1-(4-(3,4-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (R)-(3,4-dichloro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone or a pharmaceutically acceptable salt thereof. In some embodiments, the compound is (S). -(3,4-dichloro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, or a pharmaceutically acceptable salt thereof.

[0184] The compounds of the present invention also include tautomeristic forms. Tautomeristic forms result from the exchange of a single bond with an adjacent double bond, accompanied by the simultaneous transfer of a proton. Tautomeristic forms include prototropic tautomers of isomeroprotonated states having the same empirical formula and total charge. Examples of prototropic tautomers include ketone-enol pairs, amide-imido acid pairs, lactam-lactim pairs, enamine-imine pairs, and cyclic forms in which protons can occupy two or more positions in the heterocyclic system, such as 1H- and 3H-imidazoles, 1H-, 2H-, and 4H-1,2,4-triazoles, 1H- and 2H-isoindoles, and 1H- and 2H-pyrazoles. Tautomeristic forms may exist in equilibrium or can be sterically fixed into one form by appropriate substitution. Tautomeristic forms may also include methyltropic tautomers resulting from the exchange of a single bond with an adjacent double bond, accompanied by the simultaneous transfer of a methyl group.

[0185] The compounds of the present invention also include all isotopes of the atoms present in the intermediate or final compound. Isotopes include atoms with the same atomic number but different mass numbers. In some embodiments, the compounds of the present invention contain one or more isotopes of an atom in amounts greater than the natural abundance of that isotope. For example, isotopes of hydrogen include tritium and deuterium. In some embodiments, the compounds of the present invention contain at least one deuterium atom in amounts greater than the natural abundance of deuterium (for example, the compound is deuterium-rich).

[0186] All compounds described herein, and their pharmaceutically acceptable salts, may be found together with other substances such as water and solvents (for example, in the form of hydrates and solvates).

[0187] In one embodiment, the present invention relates to intermediate compounds or pharmaceutically acceptable salts thereof that can be used in the synthesis of the compounds of the present invention. For example, in some embodiments, the intermediate compound is one of the intermediate compounds from any one of Examples 1 to 194 disclosed herein or a pharmaceutically acceptable salt thereof. In some embodiments, the compound of the present invention is selected from any of the intermediate compounds disclosed in any one of Examples 1 to 194 herein or a pharmaceutically acceptable salt thereof.

[0188] The compounds of the present invention may, for example, contain one or more chiral carbon atoms and therefore may exist as stereoisomers, enantiomers, and diastereomers. Accordingly, the scope of the present invention should be understood to encompass all conceivable stereoisomers of the exemplary compounds, including stereoisomerically pure forms and mixtures of stereoisomers of any chemical structure disclosed herein, unless the stereochemistry is specifically identified. If the stereochemistry of a structure or part of a structure is not shown, for example, in bold or dashed, that structure or part of a structure should be interpreted as encompassing all of its stereoisomers. If the stereochemistry of a structure or part of a structure is shown, for example, in bold or dashed, that structure or part of a structure should be interpreted as encompassing only the stereoisomers shown.

[0189] The terms “stereoisomer” or “stereoisomerically pure” compound, as used herein, refer to one stereoisomer of a compound that substantially does not contain other stereoisomers of that compound. For example, a stereoisomerically pure compound having one chiral center substantially does not contain an enantiomer that is a mirror image of that compound, and a stereoisomerically pure compound having two chiral centers substantially does not contain other enantiomers and diastereomers of that compound. A typical stereoisomerically pure compound contains about 80% by weight of one stereoisomer and about 20% by weight or less of other stereoisomers of that compound, about 90% by weight of one stereoisomer and about 10% by weight or less of other stereoisomers of that compound, about 95% by weight of one stereoisomer and about 5% by weight or less of other stereoisomers of that compound, or about 97% by weight of one stereoisomer and about 3% by weight or less of other stereoisomers of that compound.

[0190] In some embodiments, the compounds defined herein are stereoisomerically pure.

[0191] The mixture of stereoisomers can be separated using standard techniques such as chiral columns or chiral resolving agents, as outlined in the Examples section, for example.

[0192] Pharmaceutical composition The present invention also relates to pharmaceutical compositions comprising, for example, an active ingredient, a pharmaceutically effective amount of the compounds disclosed herein. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of the compounds disclosed herein or a pharmaceutically acceptable salt thereof, together with at least one pharmaceutically acceptable carrier, excipient, and / or diluent.

[0193] The compounds disclosed herein for therapeutic use may be administered in the form of raw chemical compounds, but in many cases, it is preferable to introduce the active ingredient into a pharmaceutical composition together with one or more adjuvants, excipients, carriers, buffers, diluents, and / or other conventional pharmacovigilants, optionally in the form of pharmaceutically acceptable salts.

[0194] In some embodiments, the present invention provides pharmaceutical compositions comprising one or more pharmaceutically acceptable compounds or pharmaceutically acceptable salts thereof, together with one or more pharmaceutically acceptable carriers, and optionally other therapeutic and / or prophylactic components known and used in the art. The carrier(s) must be “acceptable” in the sense that they are compatible with the other components of the formulation and are not harmful to its recipient.

[0195] A therapeutic dose or therapeutically effective dose or size means an amount of an active ingredient, i.e., a compound or composition disclosed herein, that treats, reduces, alleviates, or reduces the severity of a disease in a subject, for example, improving one or more symptoms of the condition or the condition itself. A therapeutic dose of a compound disclosed herein may improve a patient's survival, increase survival time or survival rate, reduce symptoms, make an injury, disease, or condition (e.g., neurodegenerative disease) more tolerable, slow the rate of degeneration or debilitation, or improve a patient's physical or mental health.

[0196] Therapeutic efficacy and toxicity, e.g., ED 50 This can be determined in cell cultures or experimental animals by standard pharmacological procedures. The dose-to-therapeutic ratio is the therapeutic index, which can be expressed as the ratio of the plasma level that produces the therapeutic effect to the plasma ratio that produces the toxic effect. Pharmaceutical compositions exhibiting a large therapeutic index are preferred. In some embodiments, the therapeutically effective dose of the compounds disclosed herein ranges from about 0.01 mg / kg body weight / day to about 100 mg / kg body weight / day.

[0197] The dosage administered must, of course, be carefully adjusted to the age, weight, and condition of the individual being treated, as well as the route of administration, dosage form and regimen, and the desired outcome. The exact dosage should, of course, be determined by a specialist.

[0198] Administration refers to a method of delivering a drug, compound, or composition to the desired site of action. These methods include, but are not limited to, enteral delivery, oral delivery, topical delivery, parenteral delivery, intravenous delivery, intradermal delivery, intramuscular delivery, intrathecal delivery, colonic delivery, rectal delivery, or intraperitoneal delivery.

[0199] biological activity As demonstrated in Example 195, the compound of the present invention is K V 1.3 It is a potassium channel antagonist.

[0200] medical use K V 1,3 The compounds of the present invention, which are potassium channel antagonists, are useful for treating diseases and disorders in living organisms, including humans. As used herein, the term “treatment” includes the treatment, prevention, and / or reduction or improvement of one or more diseases and disorders, or one or more symptoms of a disease or disorder. In one embodiment, the compounds described herein are for pharmaceutically active use.

[0201] In one aspect, the present invention is K V 1.3 Formula (I) for use in the treatment of diseases or medical conditions in which inhibition of potassium channels is beneficial. [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and X 4 is C(R 17 )(R 18 ), O or C(O), X 5 is C(R 19 )(R 20 ) or combination, X 6 is a bond or C(R 21 )(R 22 ) and Here, R 9 and R 11 , R 9 and R 13 , R 10 and R 11 , R 10 and R 13 , R 13 and R 17 , R 13 and R 18 , or R 14 and R 15 They may bond together and form a ring with intervening atoms(s), R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 9 R 11 Or R 13 When R is connected to form a ring, 9 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 10 R 11 Or R 13 When R is connected to form a ring, 10 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is -X 13 -R 33 And, X 13 is a combination, C 1~3C may be substituted with alkyl. 1~3 Alkanedyl, -O-, or C 1~3 It is an alkanedyl-O-, R 33 C 1~3 Alkyl, C 3~6 Cycloalkyl, C 1~3 A C selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and morpholinyl, each of which may be substituted with a halogen, one or more fluorine atoms. 1~3 C may be substituted with alkoxy or one or more F atoms. 1~3 It may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. or R 11 R 9 Or R 10 When R is connected to form a ring, 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkandiyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • Is it acceptable for the azetidinyl to be substituted with NH2? or R 13 R 9 , R 10 , R 17 , or R 18 When R is connected to form a ring, 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 17 R 13 When R is connected to form a ring, 17 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 18 R 13 When R is connected to form a ring, 18 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If X is O, 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) and However, X 2 If X is a join, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) (is) This relates to the compound, or a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof.

[0202] In one aspect, the present invention is K V 1.3 The present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof, or pharmaceutical compositions as defined herein, for use in the treatment of diseases or medical conditions in which inhibition of potassium channels is beneficial.

[0203] In one aspect, the present invention is K V 1.3 A method for treating a disease or medical condition in which inhibition of potassium channels is beneficial, comprising administering a compound described herein or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0204] In one aspect, the present invention is K V1.3 The use of the compounds described herein or pharmaceutically acceptable salts thereof for the manufacture of pharmaceuticals for the treatment of diseases or medical conditions in which inhibition of potassium channels is beneficial.

[0205] The compounds of the present invention are used in inflammatory and autoimmune diseases, diabetes, obesity, and cancer, etc. V 1.3 It may be used in any therapy in which it is desired to treat, reduce, or alleviate the symptoms of a disease-mediated condition.

[0206] In one aspect, the present invention is K V 1.3 Relating to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the prevention and / or treatment of intermediary conditions.

[0207] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of neurodegenerative diseases. "Neurodegenerative diseases" refers to the central nervous system characterized by the progressive loss of functional nerve tissue, which is usually gradual.

[0208] In some embodiments, the neurodegenerative disease is a tauopathy. Tauopathy refers to certain neurodegenerative disorders characterized by tau deposits in the brain, accompanied by symptoms of dementia and parkinsonism. In some embodiments, the neurodegenerative disease is a tauopathy selected from the group consisting of primary age-related tauopathy (PART), spheroid glial tauopathy, chronic traumatic encephalopathy (CTE), progressive supranuclear palsy, corticobasal degeneration, diffuse neurofibrillary tangles with calcification (DNTC), frontotemporal dementia (FTD), and FTD-17 with parkinsonism (FTD-17 with parkinsonism linked to chromosome 17).

[0209] In some embodiments, the neurodegenerative disease is a neurodegenerative disorder associated with TDP-43 (TDP-43 proteinopathy or TDP-43 proteinopathy). It is evident that the brains and spinal cords of patients presenting across the spectrum of neurodegenerative diseases contain pathogenic deposits containing TAR DNA-binding protein 43 (TDP-43).

[0210] In some embodiments, neurodegenerative diseases include amyotrophic lateral sclerosis (ALS), sporadic amyotrophic lateral sclerosis (sALS), familial amyotrophic lateral sclerosis (fALS), frontotemporal lobar degeneration / disease (FTLD), primary lateral sclerosis (PLS), progressive muscular atrophy (PMA), FTLD-tau, FTLD-FUS (bvFTLD), FTLD-TDP-43 or FTLD-U (types a, b, and c), facial-onset sensorimotor neuropathy (FOSMN), limbic-dominant age-related TDP-43 encephalopathy (LATE), and age-related TDP-43 encephalopathy with sclerosis. TDP-43 proteinopathy is selected from a group of disorders that include TDP-43 conditions, including 43 (CARTS), Guam Parkinson's Dementia Complex (G-PDC) and ALS (G-ALS), Kii ALS / PDC, Amyotrophic Lateral Sclerosis / Guam Parkinson's Dementia Complex (ALS-PDC), Multisystem Proteinopathy (MSP; also known as inclusion body myopathy (IBM) with early-onset Paget's disease of bone and FTLD dementia), Perry's disease, and Alzheimer's disease (AD) and chronic traumatic encephalopathy (CTE).

[0211] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of muscular dystrophy, such as myotonic dystrophy (DM), such as type 1 DM (DM1) and type 2 DM (DM2).

[0212] In some embodiments, neurodegenerative diseases are multisystem proteinopathy (MSP). MSP is a dominant, multifaceted degenerative disorder in humans that may affect the muscles, bones, and / or the central nervous system. MSP can present clinically as classical amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), inclusion body myopathy (IBM), Paget's disease of bone (PDB), or a combination of these disorders (IBMPFD, IBMPFD / ALS).

[0213] In some embodiments, neurodegenerative diseases are synucleinopathy.

[0214] Synucleinopathy (also known as α-synucleinopathy) is a neurodegenerative disease characterized by the abnormal accumulation of aggregates of alpha-synuclein protein in neurons, nerve fibers, or glial cells.

[0215] In some embodiments, the neurodegenerative disease is a synucleinopathy selected from the group consisting of Parkinson's disease (PD), Lewy body dementia (DLB), multiple system atrophy (MSA), axonal dystrophy, and Alzheimer's disease with localized Lewy bodies in the amygdala (AD / ALB).

[0216] In some embodiments, neurodegenerative disease is agnosia and / or memory loss. In some embodiments, neurodegenerative disease is dementia. In some embodiments, neurodegenerative disease is dementia selected from the group consisting of Alzheimer's disease, Parkinson's disease dementia, Huntington's disease dementia, vascular dementia, HIV dementia, frontotemporal dementia, Lewy body dementia, prion disease dementia, argyrophilic grain dementia, Boxer dementia, Guadeloupean parkinsonism with dementia, neurofibrillary tangle-dominant dementia, neurofibrillary tangle dementia, Down syndrome, semantic dementia, familial British dementia, familial Danish dementia, as well as other dementias caused by brain tumors, subdural hematomas, endocrine disorders, nutritional deficiencies, infections, immune disorders, hepatic or renal failure, metabolic disorders such as Kufus disease, certain leukodystrophy, certain neurological disorders such as epilepsy, and other medical conditions such as multiple sclerosis.

[0217] Peripheral nerve damage (peripheral neuropathy) is the most common neurological complication of systemic amyloidosis. In some embodiments, the neurodegenerative disease is peripheral amyloidosis (peripheral neuropathy in systemic amyloidosis).

[0218] In some embodiments, the neurodegenerative disease is a demyelinating disorder. In some embodiments, the neurodegenerative disease is a demyelinating disorder of the central nervous system, i.e., the CNS. In some embodiments, the demyelinating disorder is a myelin-destroying or demyelinating disorder, selected from the group consisting of multiple sclerosis, neuromyelitis optica (Devic's disease), and idiopathic inflammatory demyelinating diseases. In some embodiments, the demyelinating disorder is a leukodystrophy or myelin-dysplasia disorder, selected from the group consisting of CNS neuropathy such as vitamin B12 deficiency, myelopathy such as central pontine myelinolysis, tabes dorsalis (syphilitic myelopathy), leukoencephalopathy, and leukodystrophy.

[0219] In some embodiments, neurodegenerative diseases are demyelinating disorders of the peripheral nervous system, i.e., the PNS. In some embodiments, demyelinating disorders are selected from the group consisting of Guillain-Barré syndrome and its corresponding chronic form, chronic inflammatory demyelinating polyneuropathy; anti-MAG peripheral neuropathy; Charcot-Marie-Tooth disease and its corresponding hereditary pressure-fragile neuropathy; copper deficiency-related conditions (peripheral neuropathy, myelopathy, and rarely optic neuropathy); and progressive inflammatory neuropathy.

[0220] In some embodiments, the neurodegenerative disease is Alzheimer's disease (AD). In some embodiments, the neurodegenerative disease is Alzheimer's disease (AD) with the R47H mutation. In some embodiments, the neurodegenerative disease is early Alzheimer's disease. In some embodiments, the neurodegenerative disease is frontotemporal lobar degeneration (FTLD). In some embodiments, the neurodegenerative disease is frontotemporal dementia. In some embodiments, the neurodegenerative disease is Parkinson's disease. In some embodiments, the neurodegenerative disease is Nasu-Hakola disease (NHD). In some embodiments, the neurodegenerative disease is FTLD-like syndrome. In some embodiments, the neurodegenerative disease is Huntington's disease. In some embodiments, the neurodegenerative disease is amyotrophic lateral sclerosis (ALS). In some embodiments, the neurodegenerative disease is multiple sclerosis (MS). In some embodiments, the neurodegenerative disease is Guillain-Barré syndrome. In some embodiments, the neurodegenerative disease is chronic inflammatory demyelinating polyneuropathy. In some embodiments, the neurodegenerative disease is progressive subcortical gliosis. In some embodiments, the neurodegenerative disease is Charcot-Marie-Tooth disease. In some embodiments, the neurodegenerative disease is a prion disease such as prion protein cerebral amyloid angiopathy. In some embodiments, the neurodegenerative disease is stroke. In some embodiments, the neurodegenerative disease is cerebral amyloid angiopathy (CAA). In some embodiments, the neurodegenerative disease is fragile X-associated ataxia tremor syndrome (FXTAS). In some embodiments, the neurodegenerative disease is herpes simplex virus (HSV) encephalitis. In some embodiments, the neurodegenerative disease is HIV-associated neurocognitive impairment (HAND). In some embodiments, the neurodegenerative disease is progressive supranuclear palsy (PSP). In some embodiments, the neurodegenerative disease is corticobasal degeneration. In some embodiments, the neurodegenerative disease is Harrellforden-Spats disease. In some embodiments, the neurodegenerative disease is globus pallidus, pontine nigra degeneration. In some embodiments, the neurodegenerative disease is post-encephalitis parkinsonism. In some embodiments, the neurodegenerative disease is subacute sclerosing panencephalitis (SSPE). In some embodiments, the neurodegenerative disease is retinal degeneration (e.g., macular degeneration).

[0221] In some embodiments, the neurodegenerative disease is leukoencephalopathy. Leukoencephalopathy (leukodystrophy-like disease) is a term used to describe all brain white matter diseases, regardless of whether the molecular cause is known or unknown. In some embodiments, the neurodegenerative disease is leukoencephalopathy selected from the group consisting of progressive multifocal leukoencephalopathy, toxic leukoencephalopathy, leukoencephalopathy with white matter disappearance, leukoencephalopathy with axonal spheroids, reversible posterior leukoencephalopathy syndrome, macrocephalic leukoencephalopathy with subcortical cysts, and hypertensive leukoencephalopathy. In some embodiments, the neurodegenerative disease is ALSP (adult-onset leukoencephalopathy with axonal spheroids and pigmentary glia).

[0222] In some embodiments, the neurodegenerative disease is selected from the group consisting of autosomal dominant cerebral arteriovenous disease with subcortical infarction or leukoencephalopathy; autosomal recessive cerebral arteriovenous disease with subcortical infarction and leukoencephalopathy; and retinal vascular disease (or cerebral retinal vascular disease) with cerebral leukoencephalopathy.

[0223] In some embodiments, the neurodegenerative disease is a leukodystrophy. In some embodiments, the neurodegenerative disease is a leukodystrophy (VWM). Leukodystrophy is a group of rare genetic disorders that affect the white matter of the brain. In some embodiments, the neurodegenerative disease is a leukodystrophy selected from the group consisting of metachromatic leukodystrophy (MLD, also known as globoid cell leukodystrophy), Krabbe disease, Canavan disease, X-linked adrenoleukodystrophy, Alexander disease, cerebral white matter hypoplasia type 7 (4H syndrome), Pelizaeus-Merzbach disease, cerebral tendon xanthomatous cerebrospinal xanthomatous disease, and leukoencephalopathy with white matter loss. In some embodiments, the neurodegenerative disease is adult-onset autosomal dominant leukodystrophy (ADLD). In some embodiments, the neurodegenerative disease is X-linked adrenoleukodystrophy (X-ALD). In some embodiments, the neurodegenerative disease is Nasu-Hakola disease, also known as polycystic lipomegaly dysplasia with sclerosing leukoencephalopathy (PLOSL).

[0224] In some embodiments, neurodegenerative diseases include Creutzfeldt-Jakob disease, Gerstmann-Streussler-Scheinker disease (GSS), Kuru, and transmissible spongiform encephalopathy (TSE), including fatal familial insomnia.

[0225] In one embodiment, the present invention relates to a method for treating neurodegenerative diseases, comprising administering a compound described herein or a pharmaceutically acceptable salt thereof to a subject in need thereof.

[0226] In one embodiment, the present invention relates to a method for treating neurodegenerative diseases, comprising one or more steps of administering a therapeutically effective amount of a compound defined herein or a pharmaceutically acceptable salt thereof to a subject in need.

[0227] In one embodiment, the present invention relates to the use of compounds described herein or pharmaceutically acceptable salts thereof for the manufacture of pharmaceuticals for the treatment of neurodegenerative diseases.

[0228] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in methods of inhibiting or reducing inflammation. In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of inflammatory conditions or disorders.

[0229] In some embodiments, the K V1.3 Intervening conditions are selected from the group consisting of inflammatory conditions, allergies and allergic conditions, hypersensitivity reactions, autoimmune diseases, severe infections, and organ or tissue transplant rejection reactions. Exemplary Kv1.3 intervening conditions include, but are not limited to, rheumatoid arthritis (RA), osteoarthritis, osteoporosis, uveitis, inflammatory fibrosis (e.g., scleroderma, pulmonary fibrosis, and cirrhosis), inflammatory bowel disorders (e.g., Crohn's disease, ulcerative colitis, and inflammatory bowel disease), multiple sclerosis, psoriasis, contact dermatitis, systemic lupus erythematosus (SLE), and other forms of lupus, diabetes mellitus, type 1 diabetes mellitus, cancer, lupus, scleroderma, Sjögren's syndrome, and vasculitis, as well as inflammatory conditions, immune and proliferative disorders.

[0230] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of lysosomal storage disorders (LSDs). Most lysosomal storage disorders cause progressive neurodegeneration leading to premature death. In some embodiments, LSD is a lipidosis, for example, selected from the group consisting of cholesteryl ester storage disease, fucosidosis, Schindler's disease, and Wolmann's disease. In some embodiments, LSD is a sphingolipidosis, for example, selected from the group consisting of Fabry disease, Gaucher disease, Krabbe disease (globoid cell leukodystrophy), metachromatic leukodystrophy (MLD), Niemann-Pick disease (types A, B, and C), Sandhoff disease, Farmer's disease, multiple sulfatase deficiencies, and Tay-Sachs disease. In some embodiments, LSD is a mucopolysaccharidosis selected from the group consisting of Hunter syndrome, Haller syndrome, Haller-Schaye syndrome, Schaye syndrome, Sanfilippo syndrome (A, B, C, D), Morquio syndrome, Maloto-Lamy syndrome, Sly syndrome, and Natowitz syndrome. In some embodiments, LSD is selected from the group consisting of Batten disease, cystinosis, Danon disease, and Pompe disease.

[0231] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of diseases or disorders of bone and / or joints. In some embodiments, the disease or disorder is selected from the group consisting of arthritis, rheumatoid arthritis, Pyle's disease, osteoporosis, osteopetrosis, osteosclerosis, skeletal dysplasia and osteodysplasia.

[0232] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of traumatic brain injury (TBI) and spinal cord injury. Traumatic brain injury (TBI) may also be known as intracranial injury. Traumatic brain injury occurs when the brain is injured by an external force. Spinal cord injury (SCI) includes any injury to the spinal cord caused by trauma instead of disease. In some embodiments, TBI is chronic traumatic encephalopathy (CTE).

[0233] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of inflammation. In some embodiments, the inflammation is selected from a group consisting of certain intestinal conditions, including inclusion body myositis, systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), gout, and inflammatory bowel disease (IBD).

[0234] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of conditions selected from the group consisting of cancer, immunological disorders, central nervous system disorders, inflammatory disorders, gastrointestinal disorders, metabolic disorders, cardiovascular disorders, and renal diseases.

[0235] K V 1.3 channel expression is associated with the regulation of proliferation, apoptosis, and cell survival in multiple cell types. These processes are important for cancer progression. Therefore, K V1.3 Channel inhibitors can be used as anticancer agents. In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of cancer. In some embodiments, cancer is selected from the group consisting of biliary tract cancer, brain cancer, breast cancer, cervical cancer, choriocarcinoma, colon cancer, endometrial cancer, esophageal cancer, gastric (stomach) cancer, carcinoma in situ, leukemia, lymphoma, liver cancer, lung cancer, melanoma, neuroblastoma, oral cancer, ovarian cancer, pancreatic cancer, prostate cancer, rectal cancer, renal (kidney) cancer, sarcoma, skin cancer, testicular cancer, and thyroid cancer.

[0236] K V 1.3 channel blockers are potential therapeutic agents as immunosuppressants or immunomodulators. The Kv1.3 channel is also considered a therapeutic target for the treatment of obesity and for enhancing peripheral insulin sensitivity in patients with type II diabetes. These compounds can also be used in the prevention of graft rejection and in the treatment of immunological (e.g., autoimmune) and inflammatory disorders. The term “autoimmune disease” generally refers to a disease in which “self” components are attacked by the immune system. Such diseases may affect a single organ, such as multiple sclerosis and type I diabetes, or may affect multiple organs, such as rheumatoid arthritis and systemic lupus erythematosus. In one embodiment, the present invention relates to compounds defined herein or pharmaceutically acceptable salts thereof for use in the treatment of autoimmune diseases. In some embodiments, the autoimmune disease is Graves' disease. In some embodiments, the autoimmune disease is Hashimoto's thyroiditis. In some embodiments, the autoimmune disease is myasthenia gravis.

[0237] Autoimmune encephalitis (AIE) is a type of encephalitis (inflammation of the brain) that can result from several autoimmune diseases, including Rasmussen's encephalitis, systemic lupus erythematosus, Behçet's disease, Hashimoto's encephalopathy, autoimmune limbic encephalitis, and Sydenham's chorea. In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of autoimmune encephalitis. In one embodiment, the AIE is selected from the group consisting of anti-NMDAR encephalitis; anti-AMPAR encephalitis; anti-GABA encephalitis such as anti-GABA-AR encephalitis and anti-GABA-BR encephalitis; anti-LGI1 encephalitis; anti-CASPR2 encephalitis; anti-GAD encephalitis; anti-GlyR encephalitis; anti-DPPX encephalitis; encephalopathy associated with anti-IgLON5 antibody; anti-mGluR1 encephalitis; and anti-mGluR5 encephalitis.

[0238] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of atopic dermatitis (eczema).

[0239] In one embodiment, the present invention relates to a compound as defined herein or a pharmaceutically acceptable salt thereof for use in the treatment of celiac disease.

[0240] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of inflammatory disorders. In some embodiments, the inflammatory disorder is an inflammatory skin condition, arthritis, psoriasis, spondylitis, periodontitis, or inflammatory neuropathy.

[0241] K V 1.3 channels play a role in gastrointestinal disorders, including but not limited to inflammatory bowel diseases such as ulcerative colitis and Crohn's disease. Ulcerative colitis is a chronic inflammatory bowel disease characterized by excessive T cell infiltration and cytokine production. V1.3 channels are thought to function as markers of disease activity, and pharmacological blockade may constitute an immunosuppressive strategy in ulcerative colitis. Crohn's disease is a type of inflammatory bowel disease that can affect any part of the gastrointestinal tract. Crohn's disease is thought to be the result of intestinal inflammation caused by a T-cell-driven process initiated by normally harmless bacteria. Therefore, K V 1.3 Channel inhibition can be used to treat Crohn's disease. In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of gastrointestinal disorders. In some embodiments, the gastrointestinal disorder is an inflammatory bowel disease such as Crohn's disease or ulcerative colitis.

[0242] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of immunological disorders. In some embodiments, the immunological disorder is transplant rejection or an autoimmune disease (e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or type 1 diabetes).

[0243] Kv1.3 channel expression is elevated in microglia of human Alzheimer's disease brains, suggesting that the Kv1.3 channel is a pathologically relevant microglial target in Alzheimer's disease. Therefore, the Kv1.3 channel may be a therapeutic target for Alzheimer's disease. In one embodiment, the present invention relates to compounds defined herein or pharmaceutically acceptable salts thereof for use in the treatment of Alzheimer's disease. In some embodiments, the central nervous system disorder is Alzheimer's disease. In some embodiments, the metabolic disorder is obesity or type 2 diabetes. In some embodiments, the renal disease is chronic kidney disease, nephritis, or chronic renal failure.

[0244] K V1.3 Channel blockers, though not limited to these, may be useful in improving the pathophysiology of cardiovascular disorders such as ischemic stroke, in which activated microglia significantly contribute to the secondary enlargement of the infarct. In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of cardiovascular disorders. In some embodiments, the cardiovascular disorder is ischemic stroke.

[0245] In some embodiments, the condition is selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Alzheimer's disease, inflammatory skin conditions, inflammatory neuropathy, psoriasis, spondylitis, periodontitis, inflammatory bowel disease, obesity, type 2 diabetes, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and combinations thereof.

[0246] In one embodiment, the present invention relates to a compound as defined herein or a pharmaceutically acceptable salt thereof for use in the treatment of bipolar disorder.

[0247] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of major depressive disorder (MDD, also known as clinical depression). In some embodiments, the MDD is selected from the group consisting of melancholic depression, atypical depression, catatonic depression, anxiety-distressing depression, perinatal depression, and seasonal affective disorder.

[0248] In one embodiment, the present invention relates to a compound as defined herein or a pharmaceutically acceptable salt thereof for use in the treatment of schizophrenia.

[0249] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of pain such as neuropathic pain or inflammatory pain.

[0250] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of CNS complications of COVID-19 infection and / or post-COVID-19 symptoms (also known as post-COVID syndrome, long COVID-19, prolonged COVID-19, and acute post-SARS-CoV-2 infection (PASC)).

[0251] In one embodiment, the present invention relates to compounds as defined herein or pharmaceutically acceptable salts thereof for use in the treatment of epilepsy, such as predisposed epilepsy or sporadic epilepsy. The term “compound” as used herein is intended to include all stereoisomers, geometric isomers, tautomers, and isotopes of the structure shown, unless otherwise specified. Therefore, the methods and uses described herein should be understood to encompass methods and uses employing all such forms.

[0252] Depending on the specific condition or disease being treated, additional therapeutic agents typically administered to treat that condition may be administered in combination with the compounds and compositions of the present invention. As used herein, additional therapeutic agents typically administered to treat a particular disease or condition are known as “appropriate for the disease or condition being treated.” In some embodiments, the combination or composition provided is administered in combination with another therapeutic agent. In some embodiments, the present invention provides a method for treating a disclosed disease or condition, comprising administering to a patient in need an effective amount of the compounds disclosed herein or a pharmaceutically acceptable salt thereof, and simultaneously or sequentially administering an effective amount of one or more additional therapeutic agents. In some embodiments, the method includes the combined administration of one or more additional therapeutic agents. Examples of therapeutic agents that may be further combined with the combinations of the present invention include, but are not limited to, therapeutic agents for Parkinson's disease, rheumatoid arthritis, Alzheimer's disease, Nasu-Hakola disease, frontotemporal dementia, multiple sclerosis, prion diseases, or stroke. In some embodiments, therapeutic agents to which the combinations of the present invention may be further combined include, but are not limited to, therapeutic agents for diseases selected from the group consisting of tauopathy, TDP-43 proteinopathy, synucleinopathy, dementia, amyloidosis, demyelinating disorders of the central nervous system (CNS), demyelinating disorders of the primary nervous system (PNS), leukoencephalopathy, leukodystrophy, transmissible spongiform encephalopathy (TSE), and lysosomal storage disorders (LSD). As used herein, the terms “combination,” “combined,” and related terms refer to the simultaneous or sequential administration of therapeutic agents according to the present invention. For example, the combinations of the present invention may be administered simultaneously or sequentially, together with another therapeutic agent, in separate unit dosage forms, or together in a single unit dosage form.

[0253] The compounds of the present invention may be used to treat animal patients belonging to any classification. Examples of such animals include mammals, such as humans, rodents, dogs, cats, zoo animals, and domestic animals. In some embodiments, the subject referred to herein is a mammal, such as a human.

[0254] In one aspect, the present invention is K V 1.3 The present invention relates to a method for blocking potassium channels in subjects requiring such blocking, comprising administering to the subject a therapeutically effective amount of at least one compound as defined herein.

[0255] In one aspect, the present invention relates to K in biological tissue. V 1.3 A method for regulating the activity, K V 1.3 is expressed in biological tissues, K V 1.3 relates to a method comprising contacting a compound as defined herein or a pharmaceutically acceptable salt thereof with an amount thereof that adjusts the compound.

[0256] In one embodiment, the present invention relates to a method for suppressing T cell activation in subjects having a condition associated with undesirable T cell activation. T cell activation can be measured by well-known methods, for example, by measuring a decrease in IL-2 production by T cells. "Suppressing T cell activation," as used herein, means the ability of a compound as defined herein or a pharmaceutically acceptable salt thereof to inhibit and reduce T cell activation by at least 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 100%.

[0257] In some embodiments, conditions associated with undesirable T cell activation include, but are not limited to, inflammatory conditions, immune and proliferative disorders, including rheumatoid arthritis (RA), osteoarthritis, osteoporosis, uveitis, inflammatory fibrosis (e.g., scleroderma, pulmonary fibrosis, and cirrhosis), inflammatory bowel disorders (e.g., Crohn's disease, ulcerative colitis, and inflammatory bowel disease), multiple sclerosis, psoriasis, contact dermatitis, systemic lupus erythematosus (SLE), and other forms of lupus, diabetes mellitus, type 1 diabetes mellitus, cancer, lupus, scleroderma, Sjögren's syndrome, and vasculitis.

[0258] Manufacturing method The compounds of the present invention can be prepared by conventional chemical synthesis methods, such as those described in the examples. The starting materials for the processes described in this application can be readily prepared by conventional methods from known or commercially available chemicals.

[0259] Substituting 2-indolecarboxylic acids are prepared using known procedures described in the literature, and in some cases, R 3 Halogen groups are introduced via halogenation reactions using known procedures and reagents, such as NCS for chlorination and Selectfluor™ for fluorination. In some cases, indole protecting groups, such as SEM, may be introduced using known procedures, which are then removed using known procedures later in the series of steps. In other cases, no protecting groups are used, and indole NH remains intact during the subsequent steps.

[0260] Scheme 1 [ka] Appropriately substituted indole-2-carboxylic acids are coupled with amines using standard procedures and reagents, e.g., EDC and HOBt, HATU, TCFH and NMI, and DIPEA and COMU (Scheme 1). In some cases, the Y protecting group (e.g., SEM) remains intact during amide bond formation and is then removed using standard procedures to obtain the desired product with Y=H. In some cases, amide bond formation occurs without protection, i.e., at Y=H.

[0261] In some cases, the indoleamide substituent contains a protecting amine (e.g., Boc protection), which is deprotected to obtain the final product, or further modified using standard procedures such as amide formation with a suitable coupling reagent (Scheme 2). In some cases, the R11 group also contains a protecting group (e.g., Boc), which is later deprotected to obtain the final product.

[0262] Scheme 2 [ka] All starting materials are commercially available or known in the art and can be synthesized using known procedures. Starting materials may also be synthesized using procedures disclosed herein. Reaction conditions, such as reaction temperature, solvent, and reagents, for the schemes in this section can be found in the Experiments section of this specification.

[0263] In one embodiment, the present invention relates to formula (I): [ka] (In the formula, R 1 , R 2 , R 3 , R 4 , R 5 , and R 6 This relates to a method for producing compounds (as defined herein).

[0264] In one embodiment, the present invention relates to formula (I): [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 4 This is defined herein, R 5 is H or halogen, R 6 (is H or halogen) A method for producing the compound, a. Equation (SI) [ka] (In the formula, R 1 is a halogen or H, R2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, Y is either H or a protecting group. The steps include preparing the compound and b. The compound in step a) [ka] (In the formula, [ka] R is defined herein. 4 or R as defined herein 4 It is reacted with its precursor to produce the formula (SII): [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, Y is either H or a protecting group. [ka] R is defined herein. 4 or R as defined herein 4 (It is a precursor of...) The step of generating the compound and This includes methods.

[0265] In some embodiments, Y is a protecting group (e.g., SEM), and a method for producing a compound of formula (I) includes a step following step b), which involves removing the protecting group. In some embodiments, Y is H.

[0266] In some embodiments, [ka] R is defined herein. 4 In some embodiments, [ka] R is defined herein. 4 It is a precursor to [something]. For example, [ka] R containing a protecting group 4 It may also be, for example, R 4 If it contains an amine, the amine may be protected (e.g., Boc protected), or R 4 If it contains an acid, the acid may be protected (for example, by an alkyl ester). Furthermore, R 4 The precursor is R as defined herein. 4 To obtain the desired result, the group may be further modified using standard procedures such as amide formation with appropriate coupling reagents. [ka] R as defined herein 4 If it is a precursor of formula (I), one or more steps are followed by step b) to obtain the compound of formula (I).

[0267] In some embodiments, Y is a protecting group, [ka] R is defined herein. 4It is a precursor of, and after step b), the protecting group at position Y is removed to form formula (SIII): [ka] The next step is c-1) which generates the compound.

[0268] Next, after step c-1), [ka] to R 4 The process is followed by step c-2), in which the compound of formula (I) is produced by modifying the formula. In some embodiments, steps c-1) and c-2) are performed simultaneously.

[0269] Alternatively, in some embodiments, Y is a protecting group, [ka] R is defined herein. 4 It is a precursor of, and after step b), [ka] to R 4 Modified to equation (SIV): [ka] Formula (SIV) The next step is to generate the compound d-1).

[0270] Next, step d-1) is followed by step d-2), in which the protecting group at position Y is removed to produce the compound of formula (I). In some embodiments, steps d-1) and d-2) are performed simultaneously.

[0271] In some embodiments, the R of formula (SI) 3 is H. In some embodiments, R of formula (SI) 3 is H, and step a) is a halogenation reaction of the compound of formula (SI) at position R 3This includes introducing a halogen to the material. In some embodiments, the halogenation reaction involves using known procedures and reagents, such as NCS for chlorination and Selectfluor® for fluorination.

[0272] item 1. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and X 4 is C(R 17 )(R 18 ), O or C(O), X 5 is C(R 19 )(R 20 ) or combination, X 6 is a bond or C(R21 )(R 22 ) and Here, R 9 and R 11 , R 9 and R 13 , R 10 and R 11 , R 10 and R 13 , R 13 and R 17 , R 13 and R 18 , or R 14 and R 15 They may bond together and form a ring with intervening atoms(s), R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R 32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 9 R 11 Or R 13 When R is connected to form a ring, 9 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, halogens such as F, or -C(O)N(R) 31 )(R32 ) and here, R 31 is H or C 1~3 It is alkyl, R 32 is H or C 1~3 Alkyl or R 10 R 11 Or R 13 When R is connected to form a ring, 10 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is -X 13 -R 33 And, X 13 is a combination, C 1~3 C may be substituted with alkyl. 1~3 Alkanedyl, -O-, or C 1~3 It is an alkanedyl-O-, R 33 C 1~3 Alkyl, C 3~6 Cycloalkyl, C 1~3 A C selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and morpholinyl, each of which may be substituted with a halogen, one or more fluorine atoms. 1~3 C may be substituted with alkoxy or one or more F atoms. 1~3 It may be substituted with one or more substituents individually selected from alkyl, NH2, N(H)(CH3), and N(CH3)2. or R 11 R 9 Or R 10 When R is connected to form a ring, 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2, or R 13 R 9 , R 10 , R 17 , or R 18 When R is connected to form a ring, 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 17 R 13 When R is connected to form a ring, 17 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 18 R 13 When R is connected to form a ring, 18 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups.1~3 It is Alkandil, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) and However, X 2 If X is a join, 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0273] 2. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and X 4 is C(R 17 )(R 18 ), O or C(O), X 5 is C(R 19 )(R 20 ) or combination, X 6 is a bond or C(R 21 )(R 22 ) and Here, R 9 and R 11 , R 9 and R 13 , R10 and R 11 , R 10 and R 13 , R 13 and R 17 , R 13 and R 18 , or R 14 and R 15 They may bond together and form a ring with intervening atoms(s), R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 9 R 11 Or R 13 When R is connected to form a ring, 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 10 R 11 Or R 13 When R is connected to form a ring, 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, and morpholinyl, where, · Said C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 The substituents may be substituted with one or more substituents individually selected from the group consisting of alkoxy, morpholinyl, azetidinyl, -O-azetidinyl, and -O-oxetanyl, wherein the azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. · Said C 3~5 Cycloalkyls are halogens, and C 1~3 It may be substituted with one or more substituents selected from alkoxys. The pyridinyl molecule may be substituted with one or more NH2 groups. • The aforementioned pyrrolidinil is C 1~3 Alkyl, halogen, C 1~3 Alkoxy, C 1~3 The molecules may be substituted with one or more substituents individually selected from the group consisting of haloalkyl, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • The aforementioned azetidinyl is a halogen, C 1~3 It may be substituted with one or more substituents selected from alkyl and NH2. • The aforementioned morpholinyl is C 1~3 Is it acceptable for it to be substituted with alkyl? or R 11 R 9 Or R 10 When R is connected to form a ring, 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2, or R 13 R 9 , R 10 , R 17 , or R 18 When R is connected to form a ring, 13 is -N(R 28 )- and here, R 28 is H or C 1~3 It is alkyl, R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is alkyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 17 R 13 When R is connected to form a ring, 17 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or halogen such as F, or R 18 R 13 When R is connected to form a ring, 18 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 19 C may be substituted with H and 1 to 3 F.1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0274] 3. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 2 is C(R 9 )(R 10 ) or combination, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, · Said C 1~3Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The aforementioned pyrrolidinil is C 1~3 Alkyl, halogen, C 1~3 The substituents may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2, or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 5 is C(R 19 )(R 20 ) or combination, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 6 is a bond or C(R 21 )(R 22 ) and R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0275] 4. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 Equation (II): [ka] (In the formula, X 1 is C(R 7 )(R 8 ) and R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, X 2 is C(R 9 )(R 10 ) or combination, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, · Said C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3They may be substituted with one or more substituents individually selected from the group consisting of alkoxys. The pyridinyl may be substituted with one or more NH2 groups. The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2. · R 11 C 1~3 Alkyl or C 1~3 If it is an alkoxy, R 11 is R 9 or R 10 They may be connected to form a ring, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and X 7 is a bond or CH2, R 23 is H or C 1~3 Alkyl or R 23 It is a bond, R 15 is C 1~3 It is an alkanedyl, R 23 is R15 It connects to form a 4 or 5-membered ring, R 24 is C 1~3 It is alkyl, R 15 is H or C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, X 5 is C(R 19 )(R 20 ) or combination, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, X 6 is a bond or C(R 21 )(R 22 ) and R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl, or F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )(C(O)R 13 ) and R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R 16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0276] 5. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is formula (XXIV), formula (XXV), formula (XXVI), or formula (XXVII): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, X 3 is N(C(O)R 11 ), C(R 12 )(C(O)R 13 ), C(R 14 )(R 15 ) or N(R 16 ) and R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, · Said C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The aforementioned pyrrolidinil is C 1~3 Alkyl, halogen, C 1~3 The substituents may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2, or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R 10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, X 4 is C(R 17 )(R 18 ), O or C(O), R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. However, X 4 If O, then X 3 is C(R 12 )C(O)R 13 And R 13 These are NH2, N(H)(CH3) or N(CH3)2, However, X 3 N(R16 ) if X 4 is C(O), However, X 4 If C(O), then X 3 is N(R 16 ) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0277] 6.Formula (LVII) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 9 and R 11 or R 10 and R 11 They may bond together and form a ring with the intervening atom. R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 9 R 11 When R is connected to form a ring, 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R10 C may be replaced by H, or 1 to 3 halogens. 1~3 Alkyl, or halogen such as F, or R 10 R 11 When R is connected to form a ring, 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 C 1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, and morpholinyl, where, · Said C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 The substituents may be substituted with one or more substituents individually selected from the group consisting of alkoxy, morpholinyl, azetidinyl, -O-azetidinyl, and -O-oxetanyl, wherein the azetidinyl is a halogen, C 1~3 Alkoxy, and C 1~3 It may be substituted with one or more substituents selected from alkyl groups. · Said C 3~5 Cycloalkyls are halogens, and C 1~3 It may be substituted with one or more substituents selected from alkoxys. The pyridinyl molecule may be substituted with one or more NH2 groups. • The aforementioned pyrrolidinil is C 1~3 Alkyl, halogen, C 1~3 Alkoxy, C 1~3 The molecules may be substituted with one or more substituents individually selected from the group consisting of haloalkyl, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. • The aforementioned azetidinyl is a halogen, C 1~3It may be substituted with one or more substituents selected from alkyl and NH2. • The aforementioned morpholinyl is C 1~3 Is it acceptable for it to be substituted with alkyl? or R 11 R 9 Or R 10 When R is connected to form a ring, 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 Any two of them may be linked together to form a ring. A compound of or a pharmaceutically acceptable salt thereof.

[0278] 7.Formula (LVII) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 It is a halogen, R 5 , R 6 , R 8 , R 17 , R 18 , R 19 , and R 20 H is H, R 9 and R 11 or R 10 and R 11 R 33 They may bond together via an intermediary atom, forming a ring with the intervening atom. R 7 C may be replaced by H, or 1 to 3 F. 1~3 It is alkyl, R 10 Is H or R 10 R 11 When R is connected to form a ring, 10 is a combination or C 1~3 It is Alkandil, R 9 Is H or R 9 R 11 When R is connected to form a ring, 9 is a combination or C 1~3 It is Alkandil, R 11 is -X 13 -R 33 And, X 13 is a combination, C 1~3 C may be substituted with alkyl. 1~3 Alkanediyl, -O-, or C 1~3 It is an alkanedyl-O-, R 33 C 1~3Alkyl, azetidinyl, pyrrolidinyl, oxetanyl, and tetrahydrofuranyl, each of which may be substituted with one or more F, or R 11 R 33 via R 9 Or R 10 When R is connected to form a ring, 33 is a combination or C 1~3 (It is Arcandil) A compound of or a pharmaceutically acceptable salt thereof.

[0279] 8. Compounds of the above formula (LVII) are of formula LVIIa): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0280] 9. However, R 4 If the expression is (XXV), then X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0281] 10. However, R 4 If is equation (XXVI), then X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0282] 11. However, R 4 If is equation (XXVII), then X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0283] 12. However, R 4 If is equation (XXVII), then equation (XXIV), then X 4 is C(R 17 )(R 18 A compound described in any one of the preceding items, which is C(O) or a pharmaceutically acceptable salt thereof.

[0284] 13.R 4 Equation (XXVIII): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0285] 14.R 4 Equation (XXIX): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0286] 15.R 4 Equation (XXIX) is given by X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0287] 16.R 4 The formula is (XXX): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0288] 17.R 4 The expression is (XXX), and X 3 is C(R12 )(C(O)R 13 ) or C(R 14 )(R 15 ) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0289] 18.R 4 Formula (XXXI): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0290] 19.R 4 Equation (XXXI) is given by X 3 is C(R 12 )(C(O)R 13 ) or C(R 14 )(R 15 ) a compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0291] 20.R 4 Equation (XXXII): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0292] 21.R 4 Equation (XXXIII): [ka] The compound described in item 4, or a pharmaceutically acceptable salt thereof.

[0293] 22. However, X 3 is N(C(O)R 11 ) or N(R 16 ) if X 2 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is not bonded.

[0294] 23. However, X 3 is N(C(O)R 11 ) or N(R 16 ) if X 5 and X 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein both are not bonded.

[0295] 24. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 This refers to formulas (III), (XXXIV), (XXXV), (XXXVI), (XXXVII), (XXXVIII), (XXXIX), or (XL): [ka] (In the formula, R 7 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 8 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 C1~3 Alkyl, C 3~5 Cycloalkyl, C 1~3 Selected from the group consisting of alkoxy, pyridinyl, azetidinyl, and pyrrolidinyl, where, · Said C 1~3 Alkyl groups include NH2, N(H)(CH3), N(CH3)2, and C 1~3 They may be substituted with one or more substituents individually selected from the group consisting of alkoxys and morpholinyls. The pyridinyl molecule may be substituted with one or more NH2 groups. • The aforementioned pyrrolidinil is C 1~3 Alkyl, halogen, C 1~3 The substituents may be substituted with one or more substituents individually selected from the group consisting of alkoxy, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2, or R 11 is R 9 It connects to form a ring, R 9 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 Is it alkyl? or R 11 is R10 It connects to form a ring, R 9 C may be replaced by H, or 1 to 3 halogens. 1~3 It is an alkyl or halogen such as F. R 10 is a bond, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 11 is halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is either -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 12 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 13 This is selected from the group consisting of NH2, N(H)(CH3), N(CH3)2, pyrrolidinyl, azetidinyl, and piperazinyl, where, The pyrrolidinyl may be substituted with one or more substituents individually selected from the group consisting of halogens, NH2, N(H)(CH3), N(CH3)2, and azetidinyl, and the azetidinyl may be substituted with one or more halogens. The aforementioned azetidinil may be substituted with NH2. R 14 is -X 7 N(R 23 )(C(O)R 24 ) and Here, X 7 is a combination or C 1~3 It is Alkandil, R 24 is C 1~3 It is alkyl, R 23 is H or C 1~3 It is alkyl, R 15 is H or C 1~3 Is it alkyl? or R 23 is a combination or C 1~3 It is an alkanedyl, R 15 is a combination or C 1~3 It is an alkanedyl, R 23 is R 15 They connect to form a ring, Alternatively, R 14 is -X 9 C(O)X 11 - and R 15 is a combination or C 1~3 It is Alkandil, X 11 is R 15 It connects to form a ring, Here, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 11 is -O-, C 1~3 Alkanedyl, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F.1~3 Alkyl or halogen such as F, R 21 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 22 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , R 20 , R 21 , and R 22 Any two of them may be linked together to form a ring. (is) A compound of or a pharmaceutically acceptable salt thereof.

[0296] 25.R 4 is formula (IV), formula (XLI), formula (XLII), formula (XLIII), formula (XLIV), formula (XLV), formula (XLVI), formula (XLVII), formula (XLVIII), formula (XLIX), or formula (L): [ka] The compound described in item 22, or a pharmaceutically acceptable salt thereof.

[0297] 26. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R6 is H or halogen, R 4 is equation (XXa) or equation (XXb): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 -CH2-, -O-, -CH2O-, -OCH2-, -N(R 28)-, or -CH2N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) (is) A compound of or a pharmaceutically acceptable salt thereof.

[0298] 27.Formula (XXIII): [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) A compound of or a pharmaceutically acceptable salt thereof.

[0299] 28. Equation (I) [ka] (In the formula, R 1 is a halogen or H, R 2 It is a halogen, R 3 is H or halogen, R 5 is H or halogen, R 6 is H or halogen, R 4 is equation (XIX): [ka] (In the formula, X 9 is a combination or -N(R 29 )- and, R 29 is C 1~3 It is alkyl, X 10 is -C(O)-, -CH2-, or a bond, X 11 is -O-, -CH2-, or -N(R 30 )- and, R 30 is C 1~3 It is alkyl, X 12 is -N(C(O)R 24 )- or combination, m is either 1 or 2. n is either 0 or 1. z is either 1 or 2, However, X 10 If is -C(O)-, then X 12 It is a combination, However, X 10 If it is a -CH2- or bond, X 12 is -N(C(O)R 24 A compound of (where ring A is a 4-6 membered ring), or a pharmaceutically acceptable salt thereof.

[0300] 29.R 1 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0301] 30.R 1 A compound described in any one of the preceding items, wherein the compound is Cl, or a pharmaceutically acceptable salt thereof.

[0302] 31.R 1 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0303] 32.R 1A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0304] 33.R 2 A compound described in any one of the preceding items, wherein the compound is Cl, or a pharmaceutically acceptable salt thereof.

[0305] 34.R 3 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0306] 35.R 3 A compound described in any one of the preceding items, wherein the compound is Cl, or a pharmaceutically acceptable salt thereof.

[0307] 36.R 3 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0308] 37.R 3 A compound, or a pharmaceutically acceptable salt thereof, that is H, as described in any one of the preceding items.

[0309] 38.R 5 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0310] 39.R 5 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0311] 40.R 5 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0312] 41.R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0313] 42.R 6A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0314] 43.R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0315] 44.R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0316] 45.R 1 is halogen, R 2 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0317] 46.R 2 is halogen, R 3 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0318] 47.R 1 is halogen, R 2 is halogen, R 3 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0319] 48.R 1 is F or Cl, and R 2 is Cl or F, and R 3 A compound described in any one of the preceding items, wherein the compound is F or Cl, or a pharmaceutically acceptable salt thereof.

[0320] 49.R 1 is halogen, R 2 is halogen, R 3 is halogen, R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0321] 50.R 1 is F or Cl, and R 2 is Cl or F, and R 3 is F or Cl, and R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0322] 51.R 1 is halogen, R 2 is halogen, R 3 H is R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0323] 52.R 1 is halogen, R 2 is halogen, R 3 H is R 5 is halogen, R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0324] 53.R 1 is halogen, R 2 is halogen, R 3 H is R 5 H is R 6 A compound described in any one of the preceding items, wherein the compound is a halogen, or a pharmaceutically acceptable salt thereof.

[0325] 54.R 1 H is R 2 is halogen, R 3 is halogen, R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0326] 55.R 1 F is R 2 Cl is and R3 A compound described in any one of the preceding items, wherein the compound is Cl, or a pharmaceutically acceptable salt thereof.

[0327] 56.R 1 F is R 2 Cl is and R 3 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0328] 57.R 1 Cl is and R 2 Cl is and R 3 A compound described in any one of the preceding items, wherein the compound is Cl, or a pharmaceutically acceptable salt thereof.

[0329] 58.R 1 Cl is and R 2 Cl is and R 3 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0330] 59.R 1 is F or Cl, and R 2 Cl is and R 3 Cl is and R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0331] 60.R 1 F is R 2 Cl is and R 3 Cl is and R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0332] 61.R 1 F is R 2 Cl is and R 3 F is R 5 H is R 6A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0333] 62.R 1 Cl is and R 2 Cl is and R 3 Cl is and R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0334] 63.R 1 Cl is and R 2 Cl is and R 3 F is R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0335] 64.R 1 Cl is and R 2 Cl is and R 3 H is R 5 F is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0336] 65.R 1 Cl is and R 2 Cl is and R 3 H is R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein F is present.

[0337] 66.R 1 Cl is and R 2 Cl is and R 3 H is R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0338] 67.R 1 F is R2 Cl is and R 3 H is R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0339] 68.R 1 H is R 2 Cl is and R 3 Cl is and R 5 H is R 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0340] 69.X 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is bonded to the compound.

[0341] 70.X 7 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is bonded to the compound.

[0342] 71.X 7 C 1~3 A compound that is an alkanediyl, as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0343] 72.X 7 A compound described in any one of the preceding items, wherein the compound is CH2, or a pharmaceutically acceptable salt thereof.

[0344] 73.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is bonded to the compound.

[0345] 74.R 4 Equation (III): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0346] 75.R 4 Equation (IV): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0347] 76.R 7 , R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0348] 77.R 4 Equation (V): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0349] 78.R 7 C such as CH3 1~3 It is alkyl, R 8 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0350] 79.R 8 C such as CH3 1~3 It is alkyl, R 7 , R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0351] 80.R 7 and R 8 C such as CH3 1~3 It is alkyl, R 9 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0352] 81.R 17 C such as CH3 1~3 It is alkyl, R 7 , R 8 , R 9 , R 10 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0353] 82.R 18 C such as CH3 1~3 It is alkyl, R 7 , R 8 , R 9 , R 10 , R 17 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0354] 83.R 17 and R 18 C such as CH31~3 It is alkyl, R 7 , R 8 , R 9 , R 10 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0355] 84.R 8 and R 17 C such as CH3 1~3 It is alkyl, R 7 , R 9 , R 10 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0356] 85.R 11 R 9 or R 10 When R is connected to form a ring, 9 or R 10 R 11 R 33 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to the above.

[0357] 86.R 9 R 33 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a ring.

[0358] 87.R 10 R 33 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a ring.

[0359] 88.R 11 C 1~3 Alkyl or C 1~3 It is an alkoxy, R 9 H is R 10 This is a bond, and R 11 R 10A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a ring.

[0360] 89.R 11 C 1~3 Alkyl or C 1~3 It is an alkoxy, R 10 H is R 9 This is a bond, and R 11 R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a ring.

[0361] 90.R 11 R 9 It connects to form a ring, R 9 C may be bonded or replaced by 1 to 3 Fs. 1~3 It is Alkandil, R 10 H is, R 11 C 1~3 It is an alkanediyl, where one methylene group is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl. A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0362] 91.R 11 R 10 It connects to form a ring, R 9 H is, R 10 C may be bonded or replaced by 1 to 3 Fs. 1~3 It is Alkandil, R 11 C 1~3 It is an alkanediyl, where one methylene group is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl. A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0363] 92.R 11 R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a five-membered ring.

[0364] 93.R 11 R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a five-membered ring.

[0365] 94.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and R 11 However, R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0366] 95.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and R 11 However, R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0367] 96.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20) and X 6 This is a bond, and R 11 However, R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0368] 97.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 This is a bond, and R 11 R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a five-membered ring.

[0369] 98.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and R 11 However, R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0370] 99.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and R 11 However, R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0371] 100.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 This is a bond, and R 11 However, R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to and forms a ring with an intervening atom.

[0372] 101.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 This is a bond, and R 11 R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a five-membered ring.

[0373] 102.R 4 Equation (LI): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy.1~3 Alkyl or halogen such as F, R 9 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 28 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0374] 103. The part of equation (LI) above is equation (LIa): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0375] 104.R 4 If equation (LI) or equation (LIa), then R 7 , R 8 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0376] 105.R 4 If equation (LI) or equation (LIa), then R 11 A compound described in any one of the preceding items, wherein the compound is -O-, or a pharmaceutically acceptable salt thereof.

[0377] 106.R 4 If equation (LI) or equation (LIa), then R 11 A compound described in any one of the preceding items, wherein the compound is -CH2-, or a pharmaceutically acceptable salt thereof.

[0378] 107.R 4 If equation (LI) or equation (LIa), then R 11 A compound described in any one of the preceding items, wherein the compound is -CH2CH2-, or a pharmaceutically acceptable salt thereof.

[0379] 108.R 4 Equation (LII): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 8 H, 1-3 F or C1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 10 is a bond, -C(O)-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is Alkandil, R 9 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 11 is -O-, -N(R 28 )-, or halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C 1~3 One methylene group in an alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 It is alkyl, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 28 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0380] 109. The part of equation (LII) above is equation (LIIa): [ka] The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0381] 110.R 4 If R is equation (LII) or equation (LIIa), 7 , R 8 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0382] 111.R 4 If R is equation (LII) or equation (LIIa), 11 A compound described in any one of the preceding items, wherein the compound is -O-, or a pharmaceutically acceptable salt thereof.

[0383] 112.R 4 If R is equation (LII) or equation (LIIa), 11 A compound described in any one of the preceding items, wherein the compound is -CH2-, or a pharmaceutically acceptable salt thereof.

[0384] 113.R 4 If R is equation (LII) or equation (LIIa), 11 A compound described in any one of the preceding items, wherein the compound is -CH2CH2-, or a pharmaceutically acceptable salt thereof.

[0385] 114.R 4 The formula is (XX): [ka] (In the formula, R 7 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3Alkyl or halogen such as F, R 8 H, 1-3 F or C 1~3 C may be substituted with alkoxy. 1~3 Alkyl or halogen such as F, R 10 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 17 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 18 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 19 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 20 C may be substituted with H and 1 to 3 F. 1~3 Alkyl or halogen such as F, R 31 These are individually halogen or C 1~3 It is alkyl, r is 0, 1, 2, 3 or 4, X 8 -CH2-, -O-, -CH2O-, -OCH2-, -N(R 28 )-, or -CH2N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0386] 115. The part of formula (XX) above is formula (XXa): [ka] Formula (XXa) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0387] 116.R 4 Equation (XXa) is given by R 7 , R 8 , R 10 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0388] 117. The part of formula (XX) above is formula (XXb): [ka] (In the formula, R 9 C may be substituted with H and 1 to 3 F. 1~3 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is an alkyl or halogen such as F.

[0389] 118.R 4 Equation (XXb) is given by R 7 , R 8 , R 9 , R 17 , R 18 , R 19 , and R 20 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

[0390] 119.R 4 Equation (XV): [ka] (In the formula, X 8 is -CH2-, -O- or -N(R 28 )- and, R 28 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0391] 120.X 8 A compound described in any one of the preceding items, wherein the compound is -CH2-, or a pharmaceutically acceptable salt thereof.

[0392] 121.X 8 A compound described in any one of the preceding items, wherein the compound is -O-, or a pharmaceutically acceptable salt thereof.

[0393] 122.X 8 ga-N(R 28 )-, the compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0394] 123.X 8 A compound described in any one of the preceding items, wherein the compound is -CH2O-, or a pharmaceutically acceptable salt thereof.

[0395] 124.X 8 A compound described in any one of the preceding items, wherein -OCH2-, or a pharmaceutically acceptable salt thereof.

[0396] 125.X 8 -CH2N(R 28 )-, the compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0397] 126.R 11 R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a six-membered ring.

[0398] 127.R 11 R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a six-membered ring.

[0399] 128.X 2 is C(R 9 )(R10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 This is a bond, and R 11 R 9 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a six-membered ring.

[0400] 129.X 2 is C(R 9 )(R 10 ) and X 3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X 6 This is a bond, and R 11 R 10 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which is linked to form a six-membered ring.

[0401] 130.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 A compound described in any one of the preceding items, wherein the compound is -O-, or a pharmaceutically acceptable salt thereof.

[0402] 131.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 However, halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 It is an alkanedyl, and here C1~3 One methylene group of the alkanediyl is -O- or -N(R 28 )- may be replaced with R 28 is H or C 1~3 A compound that is alkyl, as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0403] 132.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 However, halogen and C 1~3 C may be substituted with 1 to 3 substituents individually selected from alkyl groups. 1~3 A compound that is an alkanediyl, as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0404] 133.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 A compound described in any one of the preceding items, wherein the compound is -CH2-, or a pharmaceutically acceptable salt thereof.

[0405] 134.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 A compound described in any one of the preceding items, wherein the compound is -CH2CH2-, or a pharmaceutically acceptable salt thereof.

[0406] 135.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 A compound described in any one of the preceding items, wherein the compound is -CH2O-, or a pharmaceutically acceptable salt thereof.

[0407] 136.R 11 However, R 9 or R 10It connects with the intervening atom and forms a ring, R 11 ga-N(R 28 )-, the compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0408] 137.R 28 C 1~3 A compound that is alkyl, as described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0409] 138.R 28 A compound described in any one of the preceding items, wherein the compound is CH3, or a pharmaceutically acceptable salt thereof.

[0410] 139.R 11 However, R 9 or R 10 It connects with the intervening atom and forms a ring, R 11 A compound described in any one of the preceding items, wherein the compound is -O-, or a pharmaceutically acceptable salt thereof.

[0411] 140.R 11 However, R 9 It connects with the intervening atom and forms a ring, R 11 -R 9 The compounds described in any one of the preceding items, which are -(CH2)3-, -(CH2)O-, -(CH2)2O-, -CH2OCH2-, -C(H)(CH3)CH2-, or -C(O)N(H)-, or pharmaceutically acceptable salts thereof.

[0412] 141.R 11 However, R 10 It connects with the intervening atom and forms a ring, R 11 -R 10 The compounds described in any one of the preceding items, which are -(CH2)3-, -(CH2)O-, -(CH2)2O-, -CH2OCH2-, -C(H)(CH3)CH2-, or -C(O)N(H)-, or pharmaceutically acceptable salts thereof.

[0413] 142.X 2 is C(R 9)(R 10 ) and X 3 N(R 16 ) and X 4 C(O) and X 5 is C(R 19 )(R 20 ) and X 6 A compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, wherein the compound is bonded to the compound.

[0414] 143.R 4 Equation (VI): [ka] (In the formula, R 16 is H or C 1~3 It is alkyl, R 27 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0415] 144.R 4 is equation (VIA-1), equation (VIA-2), equation (VIB-1), or equation (VIB-2): [ka] (In the formula, R 7 is H or C 1~3 It is alkyl, R 16 is H or C 1~3 It is alkyl, R 20 is H or C 1~3 (It is alkyl.) The compound described in any one of the preceding items, or a pharmaceutically acceptable salt thereof.

[0416] 145.R 7 and R 19 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0417] 146.R 8 and R 20 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0418] 147.R 9 and R 17 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0419] 148.R 10 and R 18 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0420] 149.R 9 and R 19 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0421] 150.R 10 and R 20 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0422] 151.R 7 and R 17 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0423] 152.R 8 and R 18 However, the compounds described in any one of the preceding items, or a pharmaceutically acceptable salt thereof, which are linked together to form a bridging bicyclic ring.

[0424] 153.X 2 is C(R 9 )(R 10 ) and X3 is N(C(O)R 11 ) and X 4 is C(R 17 )(R 18 ) and X 5 is C(R 19 )(R 20 ) and X...

Claims

1. Equation (I) 【Chemistry 1】 (In the formula, R １ is a halogen or H, R ２ It is a halogen, R ３ It is a halogen, R ５ is H or halogen, R ６ is H or halogen, R ４ Equation (II): 【Chemistry 2】 (In the formula, X １ is C(R ７ )(R ８ ) and X ２ is C(R ９ ) (Caution １０ ) or combination, X ３ is N(C(O)R １１ ), C (R １２ ) (C(O)R １３ ), C (R １４ ) (Caution １５ ) or N(R １６ ) and X ４ is C(R １７ ) (Caution １８ ), O or C(O), X ５ is C(R １９ ) (Caution ２０ ) or combination, X ６ is a bond or C(R) ２１ ) (Caution ２２ ) and Here, R ９ and R １１ , R ９ and R １３ , R １０ and R １１ , R １０ and R １３ , R １３ and R １７ , R １３ and R １８ , or R １４ and R １５ They may bond together and form a ring with intervening atoms(s), R ７ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ８ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ９ C may be replaced by H, or 1 to 3 halogens. １～３ Alkyl, halogens such as F, or -C(O)N(R) ３１ ) (Caution ３２ ) and here, R ３１ is H or C １～３ It is alkyl, R ３２ is H or C １～３ Alkyl or R ９ R １１ Or R １３ When connected to form a ring, R ９ is a bond, -C(O)-, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １０ C may be replaced by H, or 1 to 3 halogens. １～３ Alkyl, halogens such as F, or -C(O)N(R) ３１ ) (Caution ３２ ) and here, R ３１ is H or C １～３ It is alkyl, R ３２ is H or C １～３ Alkyl or R １０ R １１ Or R １３ When connected to form a ring, R １０ is a bond, -C(O)-, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １１ is -X １３ -R ３３ And, X １３ C １～３ C may be substituted with alkyl. １～３ Alkanedyl, -O-, or C １～３ It is an alkanediyl-O-, R ３３ is selected from the group consisting of C １～３ alkyl, C ３～６ cycloalkyl, C １～３ alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and morpholinyl, each of which may be substituted with halogen, one or more F, C １～３ alkoxy, C １～３ alkyl optionally substituted with one or more F, NH ２ , N(H)(CH ３ ), and N(CH ３ ), and may be optionally substituted with one or more substituents individually selected from ２ ​ or R １１ is R ９ or R １０ when linked to form a ring, R １１ is -O-, -N(R ２８ ), or C １～３ alkanediyl optionally substituted with 1 to 3 substituents each independently selected from halogen and C １～３ alkanediyl, where one methylene group of the C １～３ alkanediyl may be replaced by -O- or -N(R ２８ ), and R ２８ is H or C １～３ alkyl, R １２ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R １３ NH ２ , N(H)(CH ３ ), N (CH ３ ) ２ Selected from the group consisting of pyrrolidinil, azetidinil, and piperazinil, where, - The aforementioned pyrrolidinyl is a halogen, NH ２ , N(H)(CH ３ ), N (CH ３ ) ２ The azetidinil may be substituted with one or more substituents individually selected from the group consisting of and azetidinil, and the azetidinil may be substituted with one or more halogens. - The aforementioned azetidinil is NH ２ Is it okay if it is replaced with? or R １３ R ９ , R １０ , R １７ , or R １８ When connected to form a ring, R １３ ha-N(R ２８ ) - and here, R ２８ is H or C １～３ It is alkyl, R １４ Ha - X ７ N(R) ２３ ) (C(O)R ２４ ) and Here, X ７ is a combination or C １～３ It is Alkandil, R ２４ is C １～３ It is alkyl, R ２３ is H or C １～３ It is alkyl, R １５ is H or C １～３ Is it alkyl? or R ２３ is combined or C １～３ It is an alkanedyl, R １５ is combined or C １～３ It is an alkanedyl, R ２３ is R １５ They connect to form a ring, Alternatively, R １４ is -X ９ C(O)X １１ - and R １５ is a combination or C １～３ It is Alkandil, X １１ is R １５ It connects to form a ring, Here, X ９ is bonded or -N(R) ２９ ) - and R ２９ is C １～３ It is alkyl, X １１ Ha -O-, C １～３ Alkanedyl, or -N(R) ３０ ) - and R ３０ is C １～３ It is alkyl, R １６ is H or C １～３ It is alkyl, R １７ C may be substituted with H and 1 to 3 F. １～３ Alkyl, or halogen such as F, or R １７ R １３ When connected to form a ring, R １７ is a bond, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １８ C may be substituted with H and 1 to 3 F. １～３ Alkyl, or halogen such as F, or R １８ R １３ When connected to form a ring, R １８ is a bond, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １９ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２１ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２２ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ７ , R ８ , R ９ , R １０ , R １７ , R １８ , R １９ , R ２０ , R ２１ , and R ２２ Any two of them may be linked together to form a ring. However, X ４ If X is O, ３ is C(R １２ ) C(O)R １３ And R １３ NH ２ , N(H)(CH ３ ) or N(CH ３ ) ２ And, However, X ３ N(R) １６ ) if X ４ is C(O), However, X ４ If C(O), then X ３ is N(R １６ ) and However, X ２ If X is a combination, ３ is C(R １２ ) (C(O)R １３ ) or C (R １４ ) (Caution １５ ) (is) A compound of or a pharmaceutically acceptable salt thereof.

2. R １ The compound according to claim 1, or a pharmaceutically acceptable salt thereof, wherein is a halogen.

3. R ５ H is R ６ The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein is H.

4. R １ is F or Cl, and R ２ is F or Cl, and R ３ is F or Cl, and R ５ H is R ６ A compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof, wherein the compound is H.

5. R ４ is formula (XXIV), formula (XXV), formula (XXVI), or formula (XXVII): 【Transformation 3】 A compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof.

6. R ４ Equation (III): 【Chemistry 4】 A compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof.

7. Formula (LVII) 【Transformation 5】 (In the formula, R １ is a halogen or H, R ２ It is a halogen, R ３ It is a halogen, R ５ , R ６ , R ８ , R １７ , R １８ , R １９ , and R ２０ H is, R ９ and R １１ or R １０ and R １１ R ３３ They may bond together via an intermediary atom, forming a ring with the intervening atom. R ７ C may be substituted with H or 1 to 3 F １～３ It is alkyl, R １０ is H or R １０ R １１ When connected to form a ring, R １０ is combined or C １～３ It is Alkandil, R ９ is H or R ９ R １１ When connected to form a ring, R ９ is combined or C １～３ It is Alkandil, R １１ is -X １３ -R ３３ And, X １３ C １～３ C may be substituted with alkyl. １～３ Alkanedyl, -O-, or C １～３ It is an alkanediyl-O-, R ３３ C １～３ Alkyl, azetidinyl, pyrrolidinyl, oxetanyl, and tetrahydrofuranyl, each of which may be substituted with one or more F, or R １１ R ３３ via R ９ Or R １０ When connected to form a ring, R ３３ is combined or C １～３ (It is Arcanziel) The compound according to claim 1, or a pharmaceutically acceptable salt thereof.

8. R ３３ However, halogen, C １～３ Alkoxy, and C １～３ A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, which is an azetidinyl that may be substituted with one or more substituents selected from alkyl groups.

9. R ３３ A compound according to any one of claims 1 to 6, wherein is oxetanil, or a pharmaceutically acceptable salt thereof.

10. R ３３ However, C may be substituted with halogens, one or more Fs. １～３ C may be substituted with alkoxy or one or more F atoms. １～３ A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, which is a pyrrolidinyl that may be substituted with one or more substituents individually selected from alkyl groups.

11. R ３３ A compound according to any one of claims 1 to 6, wherein is tetrahydrofuranil, or a pharmaceutically acceptable salt thereof.

12. R ３３ However, C １～３ A compound according to any one of claims 1 to 6, which is a morpholinyl that may be substituted with an alkyl group, or a pharmaceutically acceptable salt thereof.

13. R ３３ However, NH ２ , N(H)(CH ３ ), and N(CH ３ ) ２ A compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt thereof, which is a pyridinyl that may be substituted with one or more substituents individually selected from thereto.

14. R ３３ However, C may be substituted with halogens, one or more Fs. １～３ C may be substituted with alkoxy or one or more F atoms. １～３ Alkyl, NH ２ , N(H)(CH ３ ), and N(CH ３ ) ２ C may be substituted with one or more substituents individually selected from the above. １～３ A compound according to any one of claims 1 to 6, which is alkyl, or a pharmaceutically acceptable salt thereof.

15. R ３３ C １～３ A compound according to any one of claims 1 to 6, which is an alkoxy, or a pharmaceutically acceptable salt thereof.

16. R ３３ However, C may be substituted with halogens, one or more Fs. １～３ C may be substituted with alkoxy or one or more F atoms. １～３ Alkyl, NH ２ , N(H)(CH ３ ), and N(CH ３ ) ２ C may be substituted with one or more substituents individually selected from the above. ３～６ A compound according to any one of claims 1 to 6, which is a cycloalkyl compound, or a pharmaceutically acceptable salt thereof.

17. X １３ bonded, -CH ２ -, -C(H)(CH ３ )-, -O-, or -CH ２ A compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof, which is O-.

18. R １１ but, 【Transformation 6】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

19. R １１ but, 【Transformation 7】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

20. R １１ but, 【Transformation 8】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

21. R １１ but, 【Chemistry 9】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

22. R １１ but, 【Chemistry 10】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

23. R １１ but, 【Chemistry 11】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

24. R １１ However, CH ３ ien-CH ２ NH ２ ien-CH ２ -N(H)(CH ３ ), -CH ２ N(CH ３ ) ２ , -OCH ３ ien-CH ２ -O-CF ３ ien-CH ２ -O-CHF ２ , or CHF ２ The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

25. R １１ ga-OCH ３ The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

26. R １１ cyclopropyl, cyclobutyl, 【Chemistry 12】 The compound according to any one of claims 1 to 7, or a pharmaceutically acceptable salt thereof.

27. R ４ The formula (LI): 【Chemistry 13】 (In the formula, R ７ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ８ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ９ is a bond, -C(O)-, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R １１ is -O-, -N(R ２８ ) -, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is an alkanedyl, and here C １～３ One methylene group in an alkanediyl is -O- or -N(R) ２８ ) - may be replaced with R ２８ is H or C １～３ It is alkyl, R １７ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R １８ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R １９ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２８ is H or C １～３ (It is alkyl.) The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.

28. R ４ The formula is (XX): 【Chemistry 14】 (In the formula, R ７ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R ８ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R １０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R １７ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R １８ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R １９ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R ２０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen, R ３１ These are individually halogen or C １～３ It is alkyl, r is 0, 1, 2, 3 or 4, X ８ ha-CH ２ -, -O- or -N(R ２８ ) - and R ２８ is H or C １～３ (It is alkyl.) The compound according to any one of claims 1 to 4, or a pharmaceutically acceptable salt thereof.

29. R ４ The formula is (XXXIV): 【Chemistry 15】 The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.

30. R ４ Equations (XXXV), (XXXVI), and (XXXVII): 【Chemistry 16】 The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.

31. R ４ The equation is (XIX): 【Chemistry 17】 (In the formula, X ９ is bonded or -N(R) ２９ ) - and R ２９ is C １～３ It is alkyl, X １０ -C(O)-, -CH ２ -, or combination, X １１ is -O-, -CH ２ -, or -N(R ３０ ) - and R ３０ is C １～３ It is alkyl, X １２ Ha-N(C(O)R ２４ ) - or combination, m is either 1 or 2. n is either 0 or 1, z is either 1 or 2, However, X １０ If is -C(O)-, then X １２ It is a combination, However, X １０ ga-CH ２ - Or if it is a combination, X １２ Ha-N(C(O)R ２４ ) - and The compound according to any one of claims 1 to 5, wherein ring A is a 4- to 6-membered ring, or a pharmaceutically acceptable salt thereof.

32. R ４ is formula (XXXVIII), formula (XXXIX), or formula (XL): [Chemistry 18] The compound according to any one of claims 1 to 5, or a pharmaceutically acceptable salt thereof.

33. R １３ but, NH ２ , N(H)(CH ３ ), or N (CH ３ ) ２ Pyrrolidinyl may be substituted with, for example, 【Chemistry 19】 • Piperazinil, for example 【Chemistry 20】 - A pyrrolidinyl which may be substituted with azetidinil, wherein the azetidinil may be substituted with one or more halogens, for example, 【Chemistry 21】 NH ２ Azetidinil may be substituted with, for example 【Chemistry 22】 ・ NH ２ 、 • N(H)(CH ３ ), and ・ N(CH) ３ ) ２ A compound according to claim 32, or a pharmaceutically acceptable salt thereof, selected from the group consisting of the above.

34. 4-(3,4,5-trichloro-1H-indole-2-carbonyl)piperazine-2-one, 4-(4,5-dichloro-3-fluoro-1H-indole-2-carbonyl)piperazine-2-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, Methyl 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3,3-dimethylpiperazine-1yl)ethane-1-one, (S)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one, (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,5-dimethylpiperazine-2-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 2-amino-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3R)-3-(3-(dimethylamino)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, (3-(azetidine-1-yl)pyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3R)-3-(3-(3,3-difluoroazetidine-1-yl)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, (2-amino-4-pyridyl)-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]methanone, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-1,8-diazaspiro[4.5]decan-2-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethyl-1,3,8-triazaspiro[4.5]decan-2-one, (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethylpiperazine-2-one, (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydroimidazo[1,5-a]pyrazine-3(2H)-one, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(1-methylpyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (4-(6-aminonicotinoyl)piperazine-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone, (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (S)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one, (4-(2-aminoisonicotinoyl)piperazine-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone, 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-amino-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, ((3S,4R)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((3S,4S)-4-(trifluoromethyl)pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, Azethidine-3-yl (4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoroazetidine-3-carbonyl)piperazine-1-yl)methanone, ((3S,4S)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone, (S)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (R)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4-chloro-3,5-difluoro-1H-indole-2-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 2-(azetidine-3-yloxy)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, 1-(4-(3-chloro-4-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-2-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-3-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3,3-difluorocyclobutan-1-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-((1R,3R)-3-methoxycyclobutan-1-carbonyl)piperazine-1-yl)methanone, 1-(4-(3-chloro-4,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, 2-(azetidine-1-yl)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(1-methylazetidine-3-carbonyl)piperazine-1-yl)methanone, (3aR,6aR)-5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-L-prolyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one, 2-(azetidine-1-yl)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-6H-pyrido[1,2-a]pyrazine-6-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(oxetan-3-yloxy)ethane-1-one, (R)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (S)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyloctahydro-3H-pyrrolo[3,4-c]pyridine-3-one, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((3S,4S)-1-methyl-4-(trifluoromethyl)pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoro-1-methylazetidine-3-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (3-fluoroazetidine-3-yl)methyl 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, Azethidine-3-yl-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(oxetan-3-yloxy)ethane-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-8-methylhexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-(azetidine-3-yloxy)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (3aR,6aR)-5-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, 2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-3-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoropyrrolidine-1-yl)ethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluorocyclobutoxy)ethane-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-(methoxymethyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylmorpholine-2-carboxamide, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone, (S)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, (R)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2,2-difluoroethane-1-one, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(2-methyloxetane-2-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(trifluoromethoxy)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(difluoromethoxy)ethane-1-one, (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N-methylpiperazine-2-carboxamide, (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide, 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, (R)-(3,4-dichloro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, (S)-1-(4-(3,4-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one, and (R)-(3,4-dichloro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone The compound according to claim 1, or a pharmaceutically acceptable salt thereof.

35. K Ｖ 1.3 A compound according to any one of the prior claims, or a pharmaceutically acceptable salt thereof, which is a potassium channel inhibitor.

36. A pharmaceutical composition comprising a compound according to any one of the prior claims or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers, excipients and / or diluents.

37. A compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 36, for use as a pharmaceutical.

38. K Ｖ 1.3 A compound according to any one of claims 1 to 36 or a pharmaceutically acceptable salt thereof, or a pharmaceutical composition according to claim 36, for use in the treatment of a disease or medical condition in which inhibition of potassium channels is beneficial.

39. K Ｖ 1.3 Formula (I) for use in the treatment of diseases or medical conditions in which inhibition of potassium channels is beneficial: 【Chemistry 23】 (In the formula, R １ is a halogen or H, R ２ It is a halogen, R ３ is H or halogen, R ５ is H or halogen, R ６ is H or halogen, R ４ Equation (II): 【Chemistry 24】 (In the formula, X １ is C(R ７ ) (Caution ８ ) and X ２ is C(R ９ ) (Caution １０ ) or combination, X ３ is N(C(O)R １１ ), C (R １２ ) (C(O)R １３ ), C (R １４ ) (Caution １５ ) or N(R １６ ) and X ４ is C(R １７ ) (Caution １８ ), O or C(O), X ５ is C(R １９ ) (Caution ２０ ) or combination, X ６ is a bond or C(R) ２１ ) (Caution ２２ ) and Here, R ９ and R １１ , R ９ and R １３ , R １０ and R １１ , R １０ and R １３ , R １３ and R １７ , R １３ and R １８ , or R １４ and R １５ They may bond together and form a ring with intervening atoms(s), R ７ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ８ H, 1 to 3 F or C １～３ C may be substituted with an alkoxy group. １～３ Alkyl or halogen such as F, R ９ C may be replaced by H, or 1 to 3 halogens. １～３ Alkyl, halogens such as F, or -C(O)N(R) ３１ ) (Caution ３２ ) and here, R ３１ is H or C １～３ It is alkyl, R ３２ is H or C １～３ Alkyl or R ９ R １１ Or R １３ When connected to form a ring, R ９ is a bond, -C(O)-, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １０ C may be replaced by H, or 1 to 3 halogens. １～３ Alkyl, halogens such as F, or -C(O)N(R) ３１ ) (Caution ３２ ) and here, R ３１ is H or C １～３ It is alkyl, R ３２ is H or C １～３ Alkyl or R １０ R １１ Or R １３ When connected to form a ring, R １０ is a bond, -C(O)-, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １１ Ha - X １３ -R ３３ And, X １３ C １～３ C may be substituted with alkyl. １～３ Alkanedyl, -O-, or C １～３ It is an alkanediyl-O-, R ３３ C １～３ Alkyl, C ３～６ Cycloalkyl, C １～３ A C selected from the group consisting of alkoxy, pyridinyl, azetidinyl, pyrrolidinyl, oxetanyl, tetrahydrofuranyl, and morpholinyl, each of which may be substituted with a halogen, one or more fluorine atoms. １～３ C may be substituted with alkoxy or one or more F atoms. １～３ Alkyl, NH ２ , N(H)(CH ３ ), and N(CH ３ ) ２ It may be substituted with one or more substituents individually selected from there. or R １１ R ９ Or R １０ When connected to form a ring, R １１ is -O-, -N(R ２８ ) - or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is an alkanedyl, and here C １～３ One methylene group in an alkanediyl is either -O- or -N(R) ２８ ) - may be replaced with R ２８ is H or C １～３ It is alkyl, R １２ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R １３ NH ２ , N(H)(CH ３ ), N (CH ３ ) ２ Selected from the group consisting of pyrrolidinil, azetidinil, and piperazinil, where, - The aforementioned pyrrolidinyl is a halogen, NH ２ , N(H)(CH ３ ), N (CH ３ ) ２ The azetidinil may be substituted with one or more substituents individually selected from the group consisting of and azetidinil, and the azetidinil may be substituted with one or more halogens. - The aforementioned azetidinil is NH ２ Is it okay if it is replaced with? or R １３ R ９ , R １０ , R １７ , or R １８ When connected to form a ring, R １３ ha-N(R ２８ ) - and here, R ２８ is H or C １～３ It is alkyl, R １４ Ha - X ７ N(R) ２３ ) (C(O)R ２４ ) and Here, X ７ is a combination or C １～３ It is Alkandil, R ２４ is C １～３ It is alkyl, R ２３ is H or C １～３ It is alkyl, R １５ is H or C １～３ Is it alkyl? or R ２３ is combined or C １～３ It is an alkanedyl, R １５ is combined or C １～３ It is an alkanedyl, R ２３ is R １５ They connect to form a ring, Alternatively, R １４ Ha - X ９ C(O)X １１ - and R １５ is a combination or C １～３ It is Alkandil, X １１ is R １５ It connects to form a ring, Here, X ９ is bonded or -N(R) ２９ ) - and R ２９ is C １～３ It is alkyl, X １１ Ha -O-, C １～３ Alkanedyl, or -N(R) ３０ ) - and R ３０ is C １～３ It is alkyl, R １６ is H or C １～３ It is alkyl, R １７ C may be substituted with H and 1 to 3 F. １～３ Alkyl, or halogen such as F, or R １７ R １３ When connected to form a ring, R １７ is a bond, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １８ C may be substituted with H and 1 to 3 F. １～３ Alkyl, or halogen such as F, or R １８ R １３ When connected to form a ring, R １８ is a bond, or halogen and C １～３ C may be substituted with one to three substituents individually selected from alkyl groups. １～３ It is Alkandil, R １９ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２０ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２１ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ２２ C may be substituted with H and 1 to 3 F. １～３ Alkyl or halogen such as F, R ７ , R ８ , R ９ , R １０ , R １７ , R １８ , R １９ , R ２０ , R ２１ , and R ２２ Any two of them may be linked together to form a ring. However, X ４ If X is O, ３ is C(R １２ ) C(O)R １３ And R １３ NH ２ , N(H)(CH ３ ) or N(CH ３ ) ２ And, However, X ３ N(R) １６ ) if X ４ is C(O), However, X ４ If C(O), then X ３ is N(R １６ ) and However, X ２ If X is a combination, ３ is C(R １２ ) (C(O)R １３ ) or C (R １４ ) (Caution １５ ) (is) A compound of or a pharmaceutically acceptable salt thereof.

40. R １ is halogen, R ３ A compound for use according to claim 39, wherein is a halogen.

41. 4-(3,4,5-trichloro-1H-indole-2-carbonyl)piperazine-2-one, 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one, 1-[(2R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methyl-piperazine-1-yl]ethanone, 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)-2,2-dimethyl-piperazine-1-yl]ethanone, 1-[3-(4,5-dichloro-1H-indole-2-carbonyl)-3,8-diazabicyclo[3.2.1]octan-8-yl]ethanone, 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone, 1-[(3S)-4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methyl-piperazine-1-yl]ethanone, 1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]-2-(dimethylamino)ethanone, 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3,3-dimethylpiperazine-1-yl)ethane-1-one, 2-amino-1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone, 2-amino-1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]ethanone, (3R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-carboxamide, 4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-2-one, 4-(4,5-dichloro-1H-indole-2-carbonyl)-1-methylpiperazine-2-one, 4-(4,5-dichloro-6-fluoro-1H-indole-2-carbonyl)piperazine-2-one, 4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-2-one, (3R)-1-[(4,5-dichloro-1H-indole-2-yl)carbonyl]-N-methylpyrrolidine-3-carboxamide, 4-(4-chloro-1H-indole-2-carbonyl)piperazine-2-one, 1-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]-2-methoxy-ethanone, 1-(4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, 1-[4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl]-2-methoxy-ethanone, 4-(4,5-dichloro-7-fluoro-1H-indole-2-carbonyl)piperazine-2-one, 4-(4,5-dichloro-3-fluoro-1H-indole-2-carbonyl)piperazine-2-one, (S)-(4,5-dichloro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, [4-(azetidine-3-carbonyl)piperazine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone, (4,5-dichloro-1H-indole-2-yl)-[4-[(3R)-pyrrolidine-3-carbonyl]piperazine-1-yl]methanone, [4-[(2S)-azetidine-2-carbonyl]piperazine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone, (4,5-dichloro-1H-indole-2-yl)-[4-[(2S)-pyrrolidine-2-carbonyl]piperazine-1-yl]methanone, (4-(cyclopropanecarbonyl)piperazine-1-yl)(4,5-dichloro-1H-indole-2-yl)methanone, (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4,5-dichloro-1H-indole-2-yl)methanone, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, [(3R)-3-(3-aminoazetidine-1-carbonyl)pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone, [(3R)-3-[(3S)-3-aminopyrrolidine-1-carbonyl]pyrrolidine-1-yl]-(4,5-dichloro-1H-indole-2-yl)methanone, N-[1-(4-acetamidophenyl)sulfonyl-4-piperidyl]-3,5-dimethyl-1H-pyrrole-2-carboxamide, (R)-N-(1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-yl)acetamide, (R)-1-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpyrrolidine-3-carboxamide, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, Methyl 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, (S)-1-(4-(4-chloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one, 4-(4,5-dichloro-1H-indole-2-carbonyl)-N-methylmorpholine-2-carboxamide, 1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3,3-dimethylpiperazine-1yl)ethane-1-one, (S)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-2-methylpiperazine-1-yl)ethane-1-one, (S)-1-(4,5-dichloro-1H-indole-2-carbonyl)pyrrolidine-3-carboxamide (R)-1-(4-(4,5-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one, 1-(3-(4,5-dichloro-1H-indole-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-6-yl)ethane-1-one, 1-(5-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)ethane-1-one, 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-3,6-diazabicyclo[3.1.1]heptan-3-yl)ethane-1-one, 1-((2S,5R)-4-(4,5-dichloro-1H-indole-2-carbonyl)-2,5-dimethylpiperazine-1-yl)ethane-1-one, (R)-1-(4,5-dichloro-1H-indole-2-carbonyl)-N,N-dimethylpyrrolidine-3-carboxamide 1-(8-(4,5-dichloro-1H-indole-2-carbonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)ethane-1-one, (S)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)ethane-1-one, (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,5-dimethylpiperazine-2-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 2-amino-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (R)-(4,5-dichloro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, (S)-(4-chloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (R)-azetidine-2-yl(4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3R)-3-(3-(dimethylamino)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3-(azetidine-1-yl)pyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)((3R)-3-(3-(3,3-difluoroazetidine-1-yl)pyrrolidine-1-carbonyl)pyrrolidine-1-yl)methanone, (2-amino-4-pyridyl)-[4-(4,5-dichloro-1H-indole-2-carbonyl)piperazine-1-yl]methanone, 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-2,6-diazaspiro[3.4]octan-2-yl)ethane-1-one, 1-(6-(4,5-dichloro-1H-indole-2-carbonyl)-1,6-diazaspiro[3.4]octan-1-yl)ethane-1-one, 1-(7-(4,5-dichloro-1H-indole-2-carbonyl)-1,7-diazaspiro[4.4]nonane-1-yl)ethane-1-one, 1-(2-(4,5-dichloro-1H-indole-2-carbonyl)-2,6-diazaspiro[3,4]octan-6-yl)ethane-1-one, 1-(7-(4,5-dichloro-1H-indole-2-carbonyl)-2,7-diazaspiro[4,4]nonane-2-yl)ethane-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyl-2,8-diazaspiro[4.5]decan-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-1,8-diazaspiro[4.5]decan-2-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1-methyl-3-oxa-1,8-diazaspiro[4.5]decan-2-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethyl-1,3,8-triazaspiro[4.5]decan-2-one, (S)-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-1,3-dimethylpiperazine-2-one, (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydroimidazo[1,5-a]pyrazine-3(2H)-one, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (S)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-(1-methylpyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (4-(6-aminonicotinoyl)piperazine-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone, (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (S)-7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one, (4-(2-aminoisonicotinoyl)piperazine-1-yl)(3,4-dichloro-5-fluoro-1H-indole-2-yl)methanone, 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, (R)-2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-amino-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (R)-(3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, ((3S,4R)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((3S,4S)-4-(trifluoromethyl)pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, Azethidine-3-yl (4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoroazetidine-3-carbonyl)piperazine-1-yl)methanone, ((3S,4S)-3-amino-4-fluoropyrrolidine-1-yl)((R)-1-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(morpholine-3-carbonyl)piperazine-1-yl)methanone, (S)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (R)-azetidine-2-yl(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (4-(2-aminoisonicotinoyl)piperazine-1-yl)(4-chloro-3,5-difluoro-1H-indole-2-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 2-(azetidine-3-yloxy)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-prolylpiperazine-1-yl)methanone, ((R)-3-aminopyrrolidine-1-yl)((R)-1-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)pyrrolidine-3-yl)methanone, 1-(4-(3-chloro-4-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-2-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(dimethylamino)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-morpholinoethane-1-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-3-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3,3-difluorocyclobutan-1-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-((1R,3R)-3-methoxycyclobutan-1-carbonyl)piperazine-1-yl)methanone, 1-(4-(3-chloro-4,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, 2-(azetidine-1-yl)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(1-methylazetidine-3-carbonyl)piperazine-1-yl)methanone, (3aR,6aR)-5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-L-prolyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(methyl-D-prolyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one, 2-(azetidine-1-yl)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4-methylmorpholine-3-carbonyl)piperazine-1-yl)methanone, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-6H-pyrido[1,2-a]pyrazine-6-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-methoxyazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(oxetan-3-yloxy)ethane-1-one, (R)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (S)-7-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-3H-oxazolo[3,4-a]pyrazine-3-one, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoropyrrolidine-2-carbonyl)piperazine-1-yl)methanone, 5-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-2-methyloctahydro-3H-pyrrolo[3,4-c]pyridine-3-one, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((3S,4S)-1-methyl-4-(trifluoromethyl)pyrrolidine-3-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4R)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(3-fluoro-1-methylazetidine-3-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-difluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (3,4-dichloro-5-fluoro-1H-indole-2-yl)(4-((2R,4S)-4-fluoro-1-methylpyrrolidine-2-carbonyl)piperazine-1-yl)methanone, (3-fluoroazetidine-3-yl)methyl 4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, Azethidine-3-yl-4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-carboxylate, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(oxetan-3-yloxy)ethane-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, 7-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)tetrahydroimidazo[1,5-a]pyrazine-1,3(2H,5H)-dione, 2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)-8-methylhexahydropyrrolo[1,2-a]pyrazine-6(2H)-one, 2-(azetidine-3-yloxy)-1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (3aR,6aR)-5-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-2-methylhexahydropyrrolo[3,4-c]pyrrole-1(2H)-one, 2-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (R)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, (S)-2-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)hexahydro-2H,6H-pyrazino[1,2-c][1,3]oxazin-6-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-((1-methylazetidine-3-yl)oxy)ethane-1-one, 8-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)octahydro-4H-pyrazino[1,2-a]pyrazine-4-one, 1-(4-(3,4-dichloro-5-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3-fluoroazetidine-3-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoropyrrolidine-1-yl)ethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluorocyclobutoxy)ethane-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-3-(methoxymethyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)propan-1-one, (S)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one, (R)-1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoro-2-methylazetidine-1-yl)ethane-1-one, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylmorpholine-2-carboxamide, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, 4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)ethane-1-one, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone, (S)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(4,4-dimethyloxetane-2-carbonyl)piperazine-1-yl)methanone, (S)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, (R)-8-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)hexahydropyrazino[2,1-c][1,4]oxazine-4(3H)-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2,2-difluoroethane-1-one, (R)-(4-chloro-3,5-difluoro-1H-indole-2-yl)(4-(2-methyloxetane-2-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(trifluoromethoxy)ethane-1-one, 1-(4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(difluoromethoxy)ethane-1-one, (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N-methylpiperazine-2-carboxamide, (S)-4-(4-chloro-3,5-difluoro-1H-indole-2-carbonyl)-N,N-dimethylpiperazine-2-carboxamide, 1-(4-(3,4-dichloro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-methoxyethane-1-one, 1-(4-(4-chloro-3-fluoro-1H-indole-2-carbonyl)piperazine-1-yl)-2-(3,3-difluoroazetidine-1-yl)ethane-1-one, (R)-(4-chloro-3-fluoro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone, (R)-(3,4-dichloro-1H-indole-2-yl)(4-(oxetan-2-carbonyl)piperazine-1-yl)methanone, (S)-1-(4-(3,4-dichloro-1H-indole-2-carbonyl)-3-methylpiperazine-1-yl)-2-methoxyethane-1-one, or (R)-(3,4-dichloro-1H-indole-2-yl)(4-(tetrahydrofuran-2-carbonyl)piperazine-1-yl)methanone The compound for use according to claim 39, or a pharmaceutically acceptable salt thereof.

42. The compound for use according to any one of claims 38 to 41, wherein the disease or medical condition is a neurodegenerative disease.

43. The compound for use according to any one of claims 38 to 41, wherein the disease or medical condition is multiple sclerosis, Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Huntington's disease.

44. The compound for use according to claim 42, wherein the neurodegenerative disease is tauopathy, TDP-43 proteinopathy, synucleinopathy, dementia, amyloidosis, demyelinating disorder of the CNS, demyelinating disorder of the PNS, leukoencephalopathy, leukodystrophy, transmissible spongiform encephalopathy (TSE), or lysosomal storage disorder (LSD).

45. The compound for use according to claim 42, wherein the neurodegenerative disease is Alzheimer's disease, frontotemporal lobar degeneration (FTLD), frontotemporal dementia (FTD), Parkinson's disease, Nasu-Hakola disease, FTLD-like syndrome, Huntington's disease, amyotrophic lateral sclerosis, multiple sclerosis, Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, Charcot-Marie-Tooth disease, prion disease, or stroke.

46. The compound for use according to any one of claims 38 to 41, wherein the disease or medical condition is rheumatoid arthritis (RA), neuropathic pain, inflammatory pain, CNS complications of COVID-19 infection, post-COVID-19 symptoms, chronic traumatic encephalopathy, HIV-related neurocognitive disorder (HAND), traumatic brain injury, epilepsy, autoimmune encephalitis, bipolar disorder, major depressive disorder (MDD), or schizophrenia.

47. The compound for use according to any one of claims 38 to 41, wherein the disease or medical condition is psoriasis, atopic dermatitis, celiac disease, lupus, type 1 diabetes, Sjögren's syndrome, vasculitis, IBD, Crohn's disease, Graves' disease, Hashimoto's thyroiditis, myasthenia gravis, or scleroderma.

48. The compound for use according to any one of claims 38 to 41, wherein the disease or medical condition is cancer; immunological disorders such as transplant rejection or autoimmune diseases, e.g., rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, or type 1 diabetes; central nervous system disorders such as Alzheimer's disease; inflammatory disorders such as inflammatory skin conditions, arthritis, psoriasis, spondylitis, periodontitis, or inflammatory neuropathy; gastrointestinal disorders such as inflammatory bowel disease; metabolic disorders such as obesity or type 2 diabetes; cardiovascular disorders; or renal diseases such as chronic kidney disease, nephritis, or chronic renal failure.

49. The compound for use according to any one of claims 38 to 41, wherein the condition is selected from the group consisting of cancer, transplant rejection, rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus, type 1 diabetes, Alzheimer's disease, inflammatory skin conditions, inflammatory neuropathy, psoriasis, spondylitis, periodontitis, Crohn's disease, ulcerative colitis, obesity, type 2 diabetes, ischemic stroke, chronic kidney disease, nephritis, chronic renal failure, and combinations thereof.

50. K Ｖ 1.3 Use of a compound according to any one of claims 20 to 22 or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of a disease or medical condition in which inhibition of potassium channels is beneficial.

51. K Ｖ 1.3 A method for treating a disease or medical condition in which inhibition of potassium channels is beneficial, comprising administering a compound according to any one of claims 38 to 41 or a pharmaceutically acceptable salt thereof to a subject in need thereof.

52. K Ｖ 1.3 A method for blocking potassium channels in a subject requiring such blocking, comprising administering to the subject a therapeutically effective amount of at least one of the substances described in any one of claims 38 to 41, or a pharmaceutically acceptable salt thereof.

53. The method according to claim 52 or 53, wherein the subject is a mammal such as a human.

Images